U.S. patent application number 12/963572 was filed with the patent office on 2011-06-16 for compositions and methods relating to orthogonal mrna pairs.
This patent application is currently assigned to Medical Research Council. Invention is credited to Jason W. Chin, OLIVER RACKHAM.
Application Number | 20110143418 12/963572 |
Document ID | / |
Family ID | 37517116 |
Filed Date | 2011-06-16 |
United States Patent
Application |
20110143418 |
Kind Code |
A1 |
RACKHAM; OLIVER ; et
al. |
June 16, 2011 |
COMPOSITIONS AND METHODS RELATING TO ORTHOGONAL MRNA PAIRS
Abstract
Orthogonal ribosome orthogonal mRNA pairs are provided, as are
methods for their selection involving a novel positive-negative
selection approach, and methods for their use. Also provided are
cellular logic circuits involving orthogonal ribosomes.
Inventors: |
RACKHAM; OLIVER; (Cambridge,
GB) ; Chin; Jason W.; (Cambridge, GB) |
Assignee: |
Medical Research Council
|
Family ID: |
37517116 |
Appl. No.: |
12/963572 |
Filed: |
December 8, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11982877 |
Nov 6, 2007 |
7888293 |
|
|
12963572 |
|
|
|
|
PCT/GB2006/002637 |
Jul 14, 2006 |
|
|
|
11982877 |
|
|
|
|
60699936 |
Jul 15, 2005 |
|
|
|
Current U.S.
Class: |
435/193 ;
435/252.33; 435/320.1; 506/17 |
Current CPC
Class: |
C12N 15/1089 20130101;
C12N 15/11 20130101; C12N 15/67 20130101; C12N 15/1034
20130101 |
Class at
Publication: |
435/193 ; 506/17;
435/320.1; 435/252.33 |
International
Class: |
C12N 9/10 20060101
C12N009/10; C40B 40/08 20060101 C40B040/08; C12N 15/63 20060101
C12N015/63; C12N 1/21 20060101 C12N001/21 |
Claims
1. An orthogonal mRNA orthogonal rRNA pair, wherein expression of
said orthogonal rRNA is not toxic to the cell in which it is
expressed.
2. The orthogonal mRNA orthogonal rRNA pair of claim 1, wherein
said orthogonal mRNA comprises a sequence in the region from -13 to
-7, relative to the AUG initiation codon, selected from the group
consisting of: 5',.sub.-13CACCACX.sub.-7-3' (SEQ ID NO: 48, where X
is a deletion of the nucleotide at -7 relative to the AUG);
5'-.sub.-13CAACUGC.sub.-7-3' (SEQ ID NO: 49); 5'-
.sub.-13.CAUCCCU.sub.-7-3' (SEQ ID NO: 50); AND 5'-
.sub.-13UCCCUXX.sub.-7-3' ((SEQ ID NO: 51, where X is a deletion of
the nucleotides at -7 and -8 relative to the AUG).
3. The orthogonal mRNA orthogonal rRNA pair of claim 1, wherein
said orthogonal mRNA comprises a sequence immediately 5' of the AUG
initiation codon, selected from the group consisting of:
5'-CACCACCCGCAA-3' (SEQ ID NO: 52); 5'-CAACUGCCCGCAA-3' (SEQ ID NO:
53); 5'-CAUCCCUCCGCAA-3' (SEQ ID NO: 54); and 5'-UCCCUCCGCAA-3'
(SEQ ID NO: 55).
4. The orthogonal mRNA orthogonal rRNA pair of claim 1, wherein
said orthogonal rRNA comprises a sequence in the regions
corresponding to nucleotides 722-723 and 1535-1540 of E. coli 16S
rRNA selected from the group consisting of (a)-(j) below:
TABLE-US-00004 Orthogonal rRNA sequence 722-723 1535-1540 a AG
AGUGGU (SEQ ID NO: 56) b CG CUGUGG (SEQ ID Na 57) c CA UUGUGG (SEQ
ID NO: 58) d GU UUGUGG (SEQ ID NO: 59) e AC AUGCAG (SEQ ID NO: 60)
f AC UUGCAG (SEQ ID NO: 61) g CG UCGCAG (SEQ ID NO: 62) h CA CCGCAG
(SEQ ID NO: 63) i CA UGGGAU (SEQ ID NO: 64) j GU UGGGAU (SEQ ID NO:
65)
5. The orthogonal mRNA orthogonal rRNA pair of claim 1, wherein
said orthogonal rRNA comprises a sequence in the regions
corresponding to nucleotides 719-726 and 1531-1542 of E. coli 16S
rRNA selected from the group consisting of (a)-(j) below:
TABLE-US-00005 Orthogonal rRNA sequence 719-726 1531-1542 a
CCGAGUGGC AUCAAGUGGUUA (SEQ ID NO: 66) (SEQ ID NO: 67) b CCGCGUGGC
AUCACUGUGGUA (SEQ ID NO: 68) (SEQ ID NO: 69) c CCGCAUGGC
AUCAUUGUGGUA (SEQ ID NO: 70) (SEQ ID NO: 71) d CCGGUUGGC
AUCAUUGUGGUA (SEQ ID NO: 72) (SEQ ID NO: 73) e CCGACUGGC
AUCAAUGCAGUA (SEQ ID NO: 74) (SEQ ID NO: 75) f CCGACUGGC
AUCAAUGCAGUA (SEQ ID NO: 76) (SEQ ID NO: 77) g CCGCGUGGC
AUCAUCGCAGUA (SEQ ID NO: 78) (SEQ ID NO: 79) h CCGCAUGGC
AUCACCGCAGUA (SEQ ID NO: 80) (SEQ ID NO: 81) i CCGCAUGGC
AUCAUGGGALTUA (SEQ ID NO: 80) (SEQ ID NO: 82) j CCGGUUGGC
AUCAUGGGAUUA (SEQ ID NO: 83) (SEQ ID NO: 82)
6. The orthogonal mRNA orthogonal rRNA pair of claim 1, wherein
said pair comprises sequences selected from the paired mRNA and
rRNA sequences: TABLE-US-00006 Orthogonal mRNA: -13 to -7 relative
to AUG orthogonal rRNA: Pair initiation codon 722-723/1535-1540 1
5'-.sub.-13CACCACX.sub.-7-3'
5'-A.sub.722G.sub.723/1535AGUGGU.sub.1540-3' (SEQ 113 NO: 84) (SEQ
ID NO: 85) 2 5'-.sub.-13CACCACX.sub.-7-3'
5'.sup.-C.sub.722G.sub.723/1535CUGUGG.sub.1540-3' (SEQ ID NO: 84)
(SEQ ID NO: 86) 3 5'-.sub.-13CACCACX.sub.-7-3'
5'-C.sub.722A.sub.723/1535UUGUGG.sub.1540-3' (SEQ ID NO: 84) (SEQ
ID NO: 87) 4 5'-.sub.-13CACCACX.sub.-7-3'
5'-G.sub.722U.sub.723/1535UUGUGG.sub.1540-3' (SEQ ID NO: 84) (SEQ
ID NO: 87) 5 5'-.sub.-13CAACUGC.sub.-7-3'
5'-A.sub.722U.sub.723/1535AUGCAG.sub.1540-3' (SEQ ID NO: 88) (SEQ
ID NO: 89) 6 5'-.sub.-13CAACUGC.sub.-7-3'
5'-A.sub.722C.sub.723/1535UUGCAG.sub.1540-3' (SEQ ID NO: 88) (SEQ
ID NO: 90) 7 5'-.sub.-13CAACUGC.sub.-7-3'
5.sup.'-C.sub.722G7.sub.23/1535UCGCAG.sub.1540-3' (SEQ ID NO: 88)
(SEQ ID NO: 91) 8 5'-.sub.-13CAACUGC.sub.-7-3'
5.sup.'-C.sub.722A.sub.723/1535CCGCAG.sub.1540-3' (SEQ ID NO: 88)
(SEQ ID NO: 92) 9 5'-.sub.-13CAUCCCU.sub.-7-3'
5.sup.'-C.sub.722A.sub.723/1535UGGGAU.sub.1540-3' (SEQ ID NO: 93)
(SEQ ID NO: 94) 10 5'-.sub.-13CAUCCCU.sub.-7-3'
5.sup.'-C.sub.722U.sub.723/1535UGGGAU.sub.1540-3' (SEQ ID NO: 93)
(SEQ ID NO: 94)
7. The orthogonal mRNA orthogonal rRNA pair of claim 1, wherein
said pair comprises mRNA and rRNA sequences selected from the
pairs: TABLE-US-00007 Orthogonal mRNA: Orthogonal mRNA: Immediately
5' of AUG 719-726/1531-1542 relative Pair initiation codon to
E.coli 16S rRNA a 5'-CACCACCCGCAA-3' 5'-719CCGAGGGC726 (SEQ ID NO:
96).sub./ (SEQ ID NO: 95) .sub.1531AUCAAGUGGUUA.sub.1542-3' (SEQ ID
NO: 97) h 5'-CACCACCCGCAA-3' 5'-719CCGCGGGC726 (SEQ ID NO:98)/ (SEQ
ID NO: 95) .sub.1531AUCACUGUGGUA.sub.l542-3' (SEQ ID NO: 99) c
5'-CACCACCCGCAA-3' 5'-n9CCGCAGGC726 (SEQ ID NO: 100)/ (SEQ ID NO:
95) .sub.1531AUCAUUGUGGUA.sub.1542-3' (SEQ ID NO: 101) d
5'-CACCACCCGCAA-3' 5'-719CCGGUGGC (SEQ ID NO: 102)/ (SEQ ID NO: 95)
.sub.1531AUCAUUGUGGUA.sub.1542-3' (SEQ ID NO: 101) e
5'-CAACUGCCCGCAA-3' 5'-719CCGACGGC726 (SEQ ID NO: 104)/ (SEQ ID NO:
103) .sub.1531AUCAAUGCAGUA.sub.1542-3' (SEQ ID NO: 105) f
5'-CAACUGCCCGCAA-3' 5'-n9CCGACGGC726 (SEQ ID NO: 104)/ (SEQ ID NO:
103) .sub.1531AUCALJUGCAGUA.sub.1542-3' (SEQ ID NO: 106) g
5'-CAACUGCCCGCAA-3' 5'-719CCGCGGGC726 (SEQ ID NO: 107/) (SEQ ID NO:
103) .sub.1531AUCAUCGCAGUA.sub.1542-3' (SEQ ID NO: 108) h
5'-CAACUGCCCGCAA-3' 5'-719CCGCAGGC726 (SEQ ID NO: 109)/ (SEQ ID NO:
103) .sub.1531AUCACCGCAGUA.sub.1542-3' (SEQ ID NO: 110)
5'-CAUCCCUCCGCAA-3' 5'-719CCGCAGGC726 (SEQ ID NO: 109)/ (SEQ ID NO:
111) .sub.1531AUCAUGGGAUUA.sub.1542-3' (SEQ ID NO: 112) j
5'-CAUCCCUCCGCAA-3' 5'-719CCGGUGGC726 (SEQ ID NO: 113)/ (SEQ ID NO:
111) .sub.1531AUCAUGGGAUUA.sub.1542-3' (SEQ ID NO: 112) indicates
data missing or illegible when filed
8. A fusion polypeptide comprising a positive selectable marker
polypeptide and a negative selectable marker polypeptide, wherein
expression of said fusion polypeptide permits cell survival in the
presence of a positive selectable marker and renders cells
sensitive to killing by said negative selectable marker.
9. The fusion polypeptide of claim 8, wherein said positive
selectable marker comprises an antibiotic resistance coding
sequence.
10. The fusion polypeptide of claim 9, wherein said antibiotic
resistance coding sequence encodes chloramphenicol
acetyltransferase.
11. The fusion polypeptide of claim 8, wherein said negative
selectable marker comprises sequence encoding uracil
phosphoribosyltransferase.
12. The fusion polypeptide of claim 8, wherein said positive
selectable marker comprises chloramphenicol acetyltransferase and
said negative selectable marker comprises uracil
phosphoribosyltransferase.
13. The fusion polypeptide of claim 8, wherein expression of said
fusion polypeptide in a cell permits said cell to survive in the
presence of chloramphenicol and renders said cell sensitive to
killing with 5-fluorouracil.
14. The fusion polypeptide of claim 12, wherein said uracil
phosphoribosyltransferase is fused C-terminal to said
chloramphenicol acetyltransferase.
15. A vector comprising a sequence encoding a fusion polypeptide of
claim 8.
16. The vector of claim 15, wherein said sequence encoding a fusion
polypeptide is operably linked to a sequence encoding a ribosome
binding sequence.
17. The vector of claim 16, wherein said ribosome binding sequence
is a mutated ribosome binding sequence.
18. The vector of claim 17, wherein said ribosome binding sequence
comprises a mutation between -13 and +1 relative to an AUG
initiation codon at the start of said sequence encoding a fusion
polypeptide.
19. A host cell comprising a vector of claim 15.
20. A cellular logic circuit comprising an orthogonal mRNA
orthogonal ribosome pair.
21. The cellular logic circuit of claim 20, wherein said circuit
comprises a Boolean AND circuit.
22. The cellular logic circuit of claim 20, wherein said circuit
comprises a Boolean OR circuit.
23. The cellular logic circuit of claim 20, wherein said orthogonal
mRNA orthogonal rRNA pair comprises a pair selected from those
described in claim 6.
24. A cellular logic circuit or cascade comprising two or more
orthogonal mRNA orthogonal rRNA pairs recited in claim 6.
25. A method of producing a polypeptide of interest, the method
comprising: a) providing an orthogonal mRNA orthogonal rRNA pair,
wherein said orthogonal mRNA comprises sequence encoding said
polypeptide of interest; and b) introducing nucleic acid encoding
said pair to a cell, wherein translation of said orthogonal mRNA by
a ribosome comprising said orthogonal rRNA results in production of
said polypeptide.
26. The method of claim 25, wherein said orthogonal mRNA orthogonal
rRNA pair is a pair as described in claim 6.
Description
RELATED APPLICATIONS
[0001] This application is a divisional patent application which
claims priority to U.S. patent continuation patent application Ser.
No. 11/982,877 filed on Nov. 6, 2007, which claims priority to PCT
patent application number PCT/GB2006/002637, filed on Jul. 14,
2006, which claims the benefit of Provisional patent application
No. 60/699,936, filed Jul. 15, 2005, the entirety of each are
herein incorporated by reference.
FIELD OF INVENTION
[0002] The invention relates to the filed of protein translation
biochemistry. More specifically, the invention relates to
orthogonal ribosome orthogonal mRNA pairs, methods of selecting
them and their use.
BACKGROUND OF THE INVENTION
[0003] The synthesis of network of molecules to perform
well-defined functions in cells is a central aim of synthetic
biology (Gibbs, W. W., Sci Am 290, 74-81 (2004), Brent, R, Nat
Biotechnol 22, 1211-1214 (2004)). Networks have been assembled, or
evolved, from a handful of well-characterized natural transcription
factors an their binding sites (Basu, S., Gerchman, Y., Collins, C.
H., Arnold, F. H. & Weiss, R.., Nature 434, 1130-1134 (2005),
Elowitz, M. B. & Leibler, S., Nature 403, 335-338 (2000),
Gardner, T. S., Cantor, C. R. & Collins, J. J., Nature 403,
339-342 (2000), Guet C. C., Elowitz, M. B., Hsing, W. &
Leibler, S., Science 296, 1466-1470 (2002), Kaern, M. Blake, W. J.
& Collins, J. J., Annu Rev Biomed Eng 5, 179-206 (2003),
Kobayashi, H. et al., Proc Natl Acad Sci USA 101, 8414-8419 (2004),
Yokobayashi, Y., Weiss, R. & Arnold, F. H., Proc Nail Acad Sci
USA 99, 16587-16591 (2002), You, L., Cox, R. S., 3.sup.rd Weiss, R
& Arnold, F. H. Nature 428, 868-871 (2004)), to create cellular
oscillators, toggle switches and logic functions, and to create
novel modes of cell-cell communication and cell pattern
formation.
[0004] Modified ribosomes with an altered or narrowed scope of mRNA
substrates have been examined for possible use in expanding the
genetic code and for the purposes of post-transcriptional gene
regulation. Previous work has described "specialized ribosomes"
(HUI, A. S. Eaton, D. H. & de Boer, H. A., EMBO J7, 4383-4388
(1988), Hui, A., Jhurani, P. & de Boer, H. A., Methods Enzyml
153, 432-452 (1987) that bear three mutations in the SD sequence
and translate mRNAs bearing complementary mutations.in the ASD.
[0005] Lee et al. describe experiments in which random mutations
were simultaneously introduced to the rRNA binding sequence (SD) on
chloramphenicol acetyltransferase mRNA and the complementary
message-binding sequence of the E.coli 16S ASD (Lee et al., 1996,
RNA 2: 1270-1285). Alternate SD sequences that rely to varying
degrees for their translation on wild-type ribosomes were isolated
from a collection of ASD and SD mutants (Lee, K., Holland-Staley,
C. A. & Cunningham, P. R., RNA 2,1270-1285 (1996).
SUMMARY OF THE INVENTION
[0006] Orthogonal ribosome orthogonal mRNA pairs are provided, as
are methods for their selection involving a novel positive-negative
selection approach. Also provided are cellular logic circuits
involving orthogonal ribosomes.
[0007] The positive-negative selection approach uses a fusion
polypeptide comprising a positive selectable marker polypeptide
fused to a negative selectable marker in a manner that permits each
constituent of the fusion polypeptide to retain its selectable
marker function. A library of mRNAs having diversified or mutated
ribosome binding sites operably linked to the positive-negative
selectable marker fusion polypeptide is selected using the negative
selectable marker to remove mRNAs that are substrates for the
wild-type ribosome, thereby enriching for mutant mRNAs that are not
substrates for the wild-type ribosome. Cells expressing mutant
mRNAs enriched by the negative selection are then transformed with
a second library encoding small subunit rRNA molecules that are
mutated in a region comprising sequence that interacts with mRNA at
the ribosome binding site. The cells are then selected for
expression of the positive selectable marker, which enriches for
ribosomes comprising mutant small subunit rRNAs that are able to
efficiently translate the mutant mRNAs selected in the negative
selection. Resulting mRNA rRNA/ribosome pairs are orthogonal. The
orthogonal ribosome members of the pairs are not toxic when
expressed in a cell and only efficiently translate a cognate
orthogonal mRNA. The orthogonal pairs can, for example, provide
sensitively regulated novel operators to regulate cell
function.
[0008] Also provided are fusion polypeptides comprising a positive
selectable marker polypeptide and a negative selectable marker
polypeptide. The expression of the fusion polypeptide permits cell
survival in the presence of a positive selectable marker and
renders cells sensitive to killing by the negative selectable
marker. Vectors encoding such fusion polypeptides, including, but
not limited to vectors in which the coding sequences for the fusion
polypeptide are operably linked to diversified ribosome binding
sites are also provided, as are host cells comprising and/or
expressing such vectors. The positive-negative selection approach
can be applied to the selection of additional control elements,
including, for example, altered transcriptional or translational
control elements, such as riboswitches, riboregulators,
transcriptional regulators, transcription factors, RNA polymerases
and promoter sequences.
[0009] Also provided are methods of making a polypeptide of
interest using orthogonal mRNA.orthogonal ribosome pairs as
described herein. Such methods involve introducing nucleic acid
encoding such a pair to a cell, where the orthogonal mRNA encodes
the polypeptide of interest. The translation of the orthogonal mRNA
by the orthogonal ribosome (containing the orthogonal rRNA) results
in production of the polypeptide of interest. Polypeptides produced
in cells encoding orthogonal mRNA orthogonal ribosome pairs can
include unnatural amino acids.
[0010] Also provided are Boolean logic circuits programmed in cells
using one or more orthogonal ribosome orthogonal mRNA pairs such as
those described herein.
BRIEF DESCRIPTION OF THE FIGURES
[0011] FIG. 1. Creating Novel Ribosome mRNA Interactions.
[0012] The potential fates of a pair of duplicated interacting
molecules. The progenitor ribosome (black circle) interacts (black
line) with cognate progenitor mRNA (cross-hatched circle). The
diverse cellular ribosome mRNA interactions are represented by this
single interaction for simplicity. Duplication initially leads to a
second copy of the mRNA (grey circle), which is a substrate for the
progenitor ribosome and a second ribosome (checkerboard circle)
that translates the progenitor, mRNA. Numerous evolutionary fates
may befall the duplicated copies. (1) Subsequent mutations do not
alter the specificity of the mRNAs or ribosomes. (2) The duplicated
ribosome evolves to translate the duplicated and altered mRNA, but
no longer translates endogenous mRNAs. (3) The duplicated mRNA
mutates so that it is no longer a substrate for the progenitor
ribosome and the duplicated ribosome mutates so that it
promiscuously translates both the progenitor and duplicated mRNA.
(4) The duplicate ribosome accrues mutations that inactivate it,
and the duplicate mRNA remains a substrate for the progenitor
ribosome. (5) The duplicate mRNA accrues mutations, and the
duplicate ribosome continues to translate progenitor mRNAs. (6) The
duplicate ribosome and mRNA are both inactive. (7) The duplicate
mRNA accrues mutations so that it is no longer a substrate for the
progenitor ribosome. The duplicate ribosome accrues mutations so
that it no longer translates the progenitor mRNA, but does
translate the duplicate mRNA. Such ribosome mRNA pair are described
as orthogonal. Evolutionary choices in which the progenitor
molecules also evolve are not considered here.
[0013] FIG. 2. Positive and Negative Selections on Active and
Inactive Ribosome mRNA Pairs.
[0014] (a) Schematic of the selection. (b) CAT. an UPRT are
functionally expressed from cat-upp and the positive and negative
selections each have a wide dynamic range.
[0015] FIG. 3. The Design of Ribosome and mRNA Libraries for the
Selection of Orthogonal Pairs.
[0016] (a) The classic SD ASD interaction (TOP) and the nucleotides
randomized in mRNAlib and rRNAlib (BOTTOM) (See SEQ ID NOs
114-119). (b) The SD ASD interaction helix in the ribosome. The
molecular details are modeled from 5 .ANG. structures (PDB
accession numbers 1JGO and 1YL4. Image created using PyMOL:
www.pymol.org).
[0017] FIG. 4. Characterization of Potentially O-ribosome O-mRNA
Pairs.
[0018] (a) The sequences of mRNAlib and rRNAlib clones surviving
both steps of the selection. (See SEQ ID NOs 48-83). The number
(No.) of occurrences of each sequence in 51 clones is indicated to
the right of the sequence. (b) The ribosome mRNA pairs isolated
(See SEQ ID NOs 84-113). Pairs are separated into classes, on the
basis of predicted base-pairing, by grey lines. (c) Cells
transformed with mutant ribosomes do not affect growth. Each curve
is the average of at least three independent trials and the error
bars represent the standard error. (d) Selected ribosomes do not
measurably translate endogenous proteins. Cells containing the
indicated rRNA were co-transformed with plasmids in which the
cat-upp fusion was deleted (, or with the cognate mRNAlib clone
(encoding cat-upp).
Spectinomycin was added to cells to inhibit protein synthesis by
the endogenous ribosome, but not ribosomes using plasmid encoded
rRNA. (Rasmussen, U. B., Mygind, B. & Nygaard, P., Biochim
Biophys Acta 881, 268-275 (1986)). .sup.35S methionine was added to
visualize subsequent protein synthesis. Equivalent OD.sub.600s of
cells were lysed and proteins separated by SDS-PAGE.
[0019] FIG. 5. (a) Synthesis of a Post-transcriptionally Regulated
Boolean AND Function Using Orthogonal Ribosomes.
[0020] The output of the gate is .beta.-galactosidase activity,
which leads to a brown color in the presence of S-gal. (b) The
chloramphenicol resistance of cognate and non-cognate orthogonal
ribosome mRNA pairs. (c) The predicted (left) and observed (right)
network of interactions between cognate and non-cognate ribosomes
and mRNAs.
[0021] FIG. 6. An example of a bacterial phylogenetic tree based on
16S rRNA sequences.
[0022] FIG. 7. Orthogonal ribosomes-orthogonal mRNA pairs and their
network of specificities. (a) The sequence of rRNA that interacts
with mRNA is shown (wt is wild-type). WT mRNA and WT 16S rRNA are
SEQ I No: 114 and SEQ ID NO: 116 respectively. Mutations in O-mRNAs
and O-rRNAs are SEQ ID NO: 124 and SEQ ID NO: 125, respectively.
O-mRNA-B and O-rRNA-B are SEQ ID NO: 126 and SEQ ID NO: 127,
respectively. O-mRNA-B and O-rRNA-B are SEQ ID NO: 128 and SEQ ID
NO: 129., respectively. (b) Pairwise ribosome.cndot.mRNA
interaction strengths are indicated by greyscale intensity.
[0023] FIG. 8. Combinatorial logic with orthogonal ribosomes. (a)
The fluorescence generated as a function of ribosome inputs for the
AND gate. Fluorence is normalized for cell density and time of
incubation, as detailed herein below. Error bars represent the
standard error of at least three independent trials (b) Each state
of AND gate. Black lines indicate functional connections, while
grey lines indicate components that are insulated from each other.
(c,d) As for (a) and (b) but for the OR gate.
[0024] FIG. 9. Schematic of networks of Boolean AND and OR logic
gates described herein.
DESCRIPTION
Definitions
[0025] As the term "orthogonal" is used herein, it refers to an
mRNA rRNA pair (or an mRNA ribosome-comprising-an-rRNA pair) in
which the mRNA is efficiently translated by a ribosome comprising
the rRNA of the pair, but not by an endogenous ribosome, and in
which the ribosome comprising the rRNA efficiently translates the
mRNA of the pair, but not endogenous mRNAs. In this sense, the
members of the pair are well separated from other mRNAs and
rRNAs/ribosomes, in that other mRNAs can be translated by other
(e.g., endogenous) ribosomes and other ribosomes an translate a
number of different mRNAs. Thus, an "orthogonal mRNA orthogonal
rRNA pair" or O-mRNA O-rRNA pair" (or O-mRNA O-ribosome pair) is
one in which the mRNA is efficiently translated by a ribosome
containing the rRNA of the pair but not by an endogenous ribosome,
and in which a ribosome comprising the r RNA efficiently translates
the mRNA of the pair but not endogenous mRNA. In this relationship,
the members of the O-mRNA O-rRNA pair are said to be "cognate" to
each other. For simplicity, a ribosome comprising an orthogonal
rRNA is referred to herein as an "orthogonal ribosome," and an
orthogonal ribosome will efficiently translate only a cognate
orthogonal mRNA.
[0026] As used herein, the term "mRNA" when used in the context of
an O-mRNA O-ribosome pair refers to an mRNA that comprises a
ribosome binding site (particularly the sequence from the AUG
initiation codon upstream to -13 relative to the AUG) that
efficiently mediates the initiation of translation by the
O-ribosome, but not by a wild-type ribosome. The remainder of the
mRNA can vary, such that placing the coding sequence for any
protein downstream of that ribosome binding site will result in an
mRNA that is translated efficiently by the orthogonal ribosome, but
not by an endogenous ribosome.
[0027] As used herein, the term "rRNA" when used in the context of
an O-mRNA O-ribosome pair refers to a small ribosomal subunit rRNA
mutated in the 3' sequences that interact with mRNA during the
initiation of translation. The mutation(s) is/are such that the
rRNA is an orthogonal rRNA, and a ribosome containing it is an
orthogonal ribosome, i.e., it efficiently translates only a cognate
orthogonal mRNA. The primary, secondary and tertiary structures of
wild-type small ribosomal subunit rRNAs are very well known, as are
the functions of the various conserved structures (stems-loops,
hairpins, hinges, etc.). Mutations outside the 3' sequences that
interact with the mRNA during the initiation of translation are
permissible in an O-rRNA as described herein to the extent that the
O-rRNA remains orthogonal and that the mutation(s) maintain(s) the
function of the ribosome in translation (translation function is
maintained if the ribosome has at least 80%, and preferably at
least 90%, 95% or even more preferably 100% of the activity of a
corresponding ribosome with wild-type sequences outside of the 3'
sequences that interact with the mRNA during the initiation of
translation). That is, mutations outside the 3' sequences that
interact with mRNA during translation initiation should generally
be conservative or compensatory mutations that maintain the
secondary and tertiary structure of the rRNA within the ribosome
and maintain the function of the rRNA and the ribosome containing
it.
[0028] The expression of an "O-rRNA" in a cell, as the term is used
herein, is not toxic to the cell. Toxicity is measured by cell
death, or alternatively, by a slowing in the growth rate by 80% or
more relative to a cell that does not express the "O-mRNA."
Expression of an O-rRNA will preferably slow growth by less than
50%, preferably less than 25%, more preferably less than 10%, and
more preferably still, not at all, relative to the growth of
similar cells lacking the O-rRNA.
[0029] As used herein, the terms "efficiently translates" and
"efficiently mediates translation" mean that a given O-mRNA is
translated by a cognate O-ribosome at least 80% as efficiently, and
preferably at least 90%, 95% or even 100% as efficiently as an mRNA
comprising a wild-type ribosome binding sequence is translated by a
wild-type ribosome in the same cell or cell type. As a gauge, for
example, in E. coli one may evaluate translation efficiency
relative to the translation of an mRNA having a wild-type E. coli
.beta.-galactosidase ribosome binding sequence. In eukaryotic
cells, one may use as a gauge, for example, an mRNA having a
wild-type .beta.-actin ribosome binding sequence.
[0030] As used herein, the term "corresponding to" when used in
reference to nucleotide sequence means that a given sequence in one
molecule, e.g., in a 16S rRNA, is in the same position in another
molecule, e.g., a 16S rRNA from another species. By "in the same
position" is meant that the "corresponding" sequences are aligned
with each other when aligned using the BLAST sequence alignment
algorithm "BLAST 2 Sequences" described by Tatusova and Madden
(1999, "Blast 2 sequences--a new tool for comparing protein and
nucleotide sequences", FEMS Microbiol. Lett. 174:247-250) and
available from the U.S. National Center for Biotechnology
Information (NCBI). To avoid any doubt, the BLAST version 2.2.11
(available for use on the NCBI website or, alternatively, available
for download from that site) is used, with default parameters as
follows: program, blastn; reward for a match, 1; penalty for a
mismatch, -2; open gap and extend gap penalties 5 and 2,
respectively; gap x dropoff, 50; expect 10.0; word size 11; and
filter on.
[0031] As used herein, the term "selectable marker" refers to a
gene sequence that permits selection for cells in a population that
encode and express that gene sequence by the addition of a
corresponding selection agent.
[0032] As used herein, a "positive selectable marker" is a
selectable marker in which the expression of the marker is
necessary for the survival of a cell in the presence of a selection
agent. A non-limiting example of a positive selectable marker is
antibiotic resistance, in which the expression of a resistance gene
in a cell renders the cell insensitive to specific growth
retardation or killing with an antibiotic. A "corresponding"
positive selection agent is an agent that kills cells or severely
retards growth of cells lacking the positive selectable marker but
does not kill cells expressing the positive selectable marker. A
non-limiting example of a "corresponding" positive selectable agent
is an antibiotic, e.g., ampicillin or chloramphenicol where the
positive selectable marker is an antibiotic resistance gene, e.g.,
.beta.-lactamase or chloramphenicol acetyltransferase,
respectively.
[0033] As used herein, a "negative selectable marker" is a
selectable marker in which the expression of the marker renders a
cell susceptible to killing or growth retardation with a selection
agent. Non-limiting examples of negative selectable markers include
thymidine kinase (selectable with gancyclovir), B. subtilis sacB
(selectable with sucrose), and uracil phosphoribosyltransferase
(selectable with 5-fluorouracil). A "corresponding" negative
selection agent is an agent to which cells expressing the negative
selectable marker become sensitive; thus, for example, gancyclovir
"corresponds" to thymidine kinase, sucrose "corresponds" to sacB,
and 5-fluorouracil "corresponds" to uracil
phosphoribosyltransferase in the preceding examples.
[0034] As used herein, the term "chloramphenicol acetyltransferase"
refers to an enzyme that catalyzes the acetylation of
chloramphenicol which renders the chloramphenicol inactive for
translation blockade and inactive for cell killing. Assays for
measuring acetylation of chloramphenicol by chloramphenicol
acetyltransferase are well known in the art.
[0035] As used herein, the term "growth retardation" means that in
cells sensitive to such retardation, the doubling time of bacteria
is at least two times as long as in insensitive bacteria,
preferably at least three, four or five times or more longer,
relative to cells that are not sensitive to the retardation. Over
the time course of multiple doublings for an insensitive cell, the
proportion of the population of insensitive cells will rapidly
become dominant, e.g., 95%, 99% or more, relative to sensitive
cells.
[0036] The term "uracil phosphoribosyltransferase" refers to an
enzyme that catalyzes the phosphorylation of uracil to uridine
monophosphate.
[0037] As used herein, "survival in the presence of
chloramphenicol" means that a cell expressing chloramphenicol
acetyltransferase will survive in medium containing chloramphenicol
at a concentration in which 100% of cells that do not express
chloramphenicol acetyltransferase are killed or severely growth
retarded. "Severely" growth retarded means an increase in doubling
time of 5 times or more relative to non-retarded growth.
[0038] As used herein, "sensitive to killing with 5-fluorouracil"
means that all cells in a population expressing a CAT/UPRT fusion
as described herein are killed at a concentration of 5-FU greater
than or equal to 0.1 .mu.g/ml.
[0039] As used herein, the term "region comprising sequence that
interacts with mRNA at the ribosome binding site" refers to a
region of sequence comprising the nucleotides near the 3' terminus
of 16S rRNA that physically interact, e.g., by base pairing or
other interaction, with mRNA during the initiation of translation.
The "region" includes nucleotides that base pair or otherwise
physically interact with nucleotides in mRNA at the ribosome
binding site, and nucleotides within five nucleotides 5' or 3' of
such nucleotides. Also included in this "region" are bases
corresponding to nucleotides 722 and 723 of the E. coli 16S rRNA,
which form a bulge proximal to the minor groove of the
Shine-Dalgarno helix formed between the ribosome and mRNA.
[0040] As used herein, the term "diversified" means that individual
members of a library will vary in sequence at a given site. Methods
of introducing diversity are well known to those skilled in the
art, and can introduce random or less than fully random diversity
at a given site. By "fully random" is meant that a given nucleotide
can be any of G, A, T, or C (or in RNA, any of G, A, U and C). By
"less than fully random" is meant that a given site can be occupied
by more than one different nucleotide, but not all of G, A, T (U in
RNA) or C, for example where diversity permits either G or A, but
not U or C, or permits G, A, or U but not C at a given site.
[0041] As used herein, the term "ribosome binding site" refers to
the region of an mRNA that is bound by the ribosome at the
initiation of translation. As defined herein, the "ribosome binding
site" of prokaryotic mRNAs includes the Shine-Dalgarno consensus
sequence and nucleotides -13 to +1 relative to the AUG initiation
codon.
[0042] As used herein, the term "unnatural amino acid" refers to an
amino acid other than the 20 amino acids that occur naturally in
protein. Non-limiting examples include: a p-acetyl-L-phenylalanine,
a p-iodo-L-phenylalanine, an O-methyl-L-tyrosine, a
p-propargyloxyphenylalanine, a p-propargyl-phenylalanine, an
L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an
O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a
tri-O-acetyl-GlcNAc.beta.-serine, an L-Dopa, a fluorinated
phenylalanine, an isopropyl-L-phenylalanine, a
p-azido-L-phenylalanine, a p-acyl-L-phenylalanine, a
p-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphonoserine, a
phosphonotyrosine, a p-bromophenylalanine, a
p-amino-L-phenylalanine, an isopropyl-L-phenylalanine, an unnatural
analogue of a tyrosine amino acid; an unnatural analogue of a
glutamine amino acid; an unnatural analogue of a phenylalanine
amino acid; an unnatural analogue of a serine amino acid; an
unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl,
azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl,
alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate,
boronate, phospho, phosphono, phosphine, heterocyclic, enone,
imine, aldehyde, hydroxylamine, keto, or amino substituted amino
acid, or a combination thereof; an amino acid with a
photoactivatable cross-linker; a spin-labeled amino acid; a
fluorescent amino acid; a metal binding amino acid; a
metal-containing amino acid; a radioactive amino acid; a photocaged
and/or photoisomerizable amino acid; a biotin or biotin-analogue
containing amino acid; a keto containing amino acid; an amino acid
comprising polyethylene glycol or polyether; a heavy atom
substituted amino acid; a chemically cleavable or photocleavable
amino acid; an amino acid with an elongated side chain; an amino
acid containing a toxic group; a sugar substituted amino acid; a
carbon-linked sugar-containing amino acid; a redox-active amino
acid; an .alpha.-hydroxy containing acid; an amino thio acid; an
.alpha., .alpha. disubstituted amino acid; a .beta.-amino acid; a
cyclic amino acid other than proline or histidine, and an aromatic
amino acid other than phenylalanine, tyrosine or tryptophan.
[0043] As used herein, the term "logic circuit" refers to a set of
interacting parameters with a read out that announces the state of
the interacting parameters. For example, a "Boolean AND circuit"
refers to a set of two entities or conditions, A and B, that must
be present or satisfied to give read-out C. Read-out C is only
given when conditions A AND B are satisfied. A "Boolean OR circuit"
refers to a set of two entities or conditions A and B, and a
read-out D. In the OR circuit, read-out D is given, for example,
when A OR B are satisfied. Thus, if A OR B is satisfied, read-out D
is given in the OR circuit. A "cellular" logic circuit is a logic
circuit as defined herein in which the entities of the logic
circuit necessary to provide a read-out are expressed in a living
cell. As used herein, the term "cascade" refers to a series of
logic circuits in which the result of one circuit is required as an
element in a second circuit.
DETAILED DESCRIPTION
[0044] Synthetic biology aims for the ability to program cells with
new functions. Simple oscillators, switches, logic functions,
cell-cell communication and pattern forming circuits have been
created, by the connection of a small set of natural transcription
factors and their binding sites in different ways to create
different networks of molecular interactions. However, the
controlled synthesis of more complex synthetic networks and
functions requires an expanded set of functional molecules with
known molecular specificities.
[0045] Networks of molecular interactions in organisms have evolved
to allow the increase in complexity from unicelllular organisms to
metazoans (Ohno, S., Springer-Verlag, Heidelberg, New York; 1970),
Taylor, J. S. & Raes, J., Annu Rev Genet 38, 615-643 (2004),
Teichmann, S. A. & Babu, M. M., Nat Genet 36, 492-496 (2004))
through duplication of a progenitor gene followed by the
acquisition of a novel function (neofunctionalization) in the
duplicated copy. Described herein are processes that artificially
mimic the natural process to produce orthogonal molecules: that is,
molecules that can process information in parallel with their
progenitors without cross-talk between the progenitors and the
duplicated molecules. Using these processes, it is now possible to
tailor the evolutionary fates of a pair of duplicated molecules
from amongst the many natural fates to give a predetermined
relationship between the duplicated molecules and the progenitor
molecules from which they are derived (see, e.g., FIG. 1). This is
exemplified herein by the generation of orthogonal ribosome
orthogonal mRNA pairs that can process information in parallel with
wild-type ribosomes and mRNA but that do not engage in cross-talk
between the wild-type and orthogonal molecules.
[0046] The bacterial ribosome is a 2.5 MDa complex of rRNA and
protein responsible for translation of mRNA into protein (The
Ribosome, Vol. LXVI. (Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, New York; 2001). The interaction between the mRNA
and the 30S subunit of the ribosome is an early event in
translation (Laursen, B. S., Sorensen, H. P., Mortensen, K. K.
& Sperling-Petersen, H. U., Microbiol Mol Biol Rev 69, 101-123
(2005)), and several features of the mRNA are known to control the
expression of a gene, including the first codon (Wikstrom, P. M.,
Lind, L. K., Berg, D. E. & Bjork, G. R., J Mol Biol 224,
949-966 (1992)), the ribosome-binding sequence (including the Shine
Dalgarno (SD) sequence (Shine, J. & Dalgarno, L., Biochem J
141, 609-615 (1974), Steitz, J. A. & Jakes, K., Proc Nail Acad
Sci USA 72, 4734-4738 (1975), Yusupova, G. Z., Yusupov, M. M.,
Cate, J. H. & Noller, H. F., Cell 106, 233-241 (2001)), and the
spacing between these sequences (Chen, H., Bjerknes, M., Kumar, R.
& Jay, E., Nucleic Acids Res 22, 4953-4957 (1994)). In certain
cases mRNA structure (Gottesman, S. et al. in The Ribosome, Vol.
LXVI (Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y.; 2001), Looman, A. C., Bodlaender, J., de Gruyter, M.,
Vogelaar, A. & van Knippenberg, P. H., Nucleic Acids Res 14,
5481-5497 (1986)), Liebhaber, S. A., Cash, F. & Eshleman, S.
S., J Mol Biol 226, 609-621 (1992), or metabolite binding (Winkler,
W., Nahvi, A. & Breaker, R. R., Nature 419, 952-956 (2002)),
influences translation initiation, and in rare cases mRNAs can be
translated without a SD sequence, though translation of these
sequences is inefficient (Laursen, B. S., Sorensen, H. P.,
Mortensen, K. K. & Sperling-Petersen, H. U., Microbiol Mol Biol
Rev 69, 101-123 (2005)), and operates through an alternate
initiation pathway, Laursen, B. S., Sorensen, H. P., Mortensen, K.
K. & Sperling-Petersen, H. U. Initiation of protein synthesis
in bacteria. Microbiol Mol Biol Rev 69, 101-123 (2005). For the
vast majority of bacterial genes the SD region of the mRNA is a
major determinant of translational efficiency. The classic SD
sequence GGAGG (SEQ ID NO: 1) interacts through RNA-RNA
base-pairing with a region at the 3' end of the 16S rRNA containing
the sequence CCUCC (SEQ ID NO: 2), known as the Anti Shine Dalgarno
(ASD). In E. coli there are an estimated 4,122 translational starts
(Shultzaberger, R. K., Bucheimer, R. E., Rudd, K. E. &
Schneider, T. D., J Mol Biol 313, 215-228 (2001)), and these differ
in the spacing between the SD-like sequence and the AUG start
codon, the degree of complementarity between the SD-like sequence
and the ribosome, and the exact region of sequence at the 3' end of
the 16S rRNA with which the mRNA interacts. The ribosome therefore
drives translation from a more complex set of sequences than just
the classic Shine Dalgarno (SD) sequence. For clarity, mRNA
sequences believed to bind the 3' end of 16S rRNA are referred to
as SD sequences and to the specific sequence GGAGG (SEQ ID NO: 1)
is referred to as the classic SD sequence.
[0047] Mutations in the SD sequence often lead to rapid cell lysis
and death (Lee, K., Holland-Staley, C. A. & Cunningham, P. R.,
RNA 2, 1270-1285 (1996), Wood, T. K. & Peretti, S. W.,
Biotechnol. Bioeng 38, 891-906 (1991)). Such mutant ribosomes
mis-regulate cellular translation and are not orthogonal. The
sensitivity of cell survival to mutations in the ASD region is
underscored by the observation that even a single change in the ASD
can lead to cell death through catastrophic and global
mis-regulation of proteome synthesis (Jacob, W. F., Santer, M.
& Dahlberg, A. E., Proc Natl Acad Sci U S A 84, 4757-4761
(1987). Other mutations in the rRNA can lead to inadequacies in
processing or assembly of functional ribosomes.
[0048] Methods are described herein, for example, for tailoring the
molecular specificity of duplicated E. coli ribosome mRNA pairs
with respect to the wild-type ribosome and mRNAs to produce
multiple orthogonal ribosome orthogonal mRNA pairs. In these pairs
the ribosome efficiently translates only the orthogonal mRNA and
the orthogonal mRNA is not an efficient substrate for cellular
ribosomes. Orthogonal ribosomes as described herein that do not
translate endogenous mRNAs permit specific translation of desired
cognate mRNAs without interfering with cellular gene expression.
The network of interactions between these orthogonal pairs is
predicted and measured, and it is shown herein that orthogonal
ribosome mRNA pairs can be used to post-transcriptionally program
the cell with Boolean logic.
[0049] Finding orthogonal ribosome orthogonal mRNA pairs requires
the discovery of ribosome variants that specify the translation of
the orthogonal mRNA with high efficiency. These ribosome variants
must not interfere with ribosome assembly, rRNA processing or
cellular viability, and must not significantly or detrimentally
translate any of the thousands of endogenous transcripts. In
addition it requires the discovery of an orthogonal mRNA that is
robustly translated by only the orthogonal ribosome, but is not a
substrate for the endogenous ribosome.
[0050] A selection approach for the discovery of orthogonal
ribosome mRNA pairs can permit the interrogation of up to 10.sup.9
times more sequence space than has previously been considered by
small screens or designed mutants. Described herein is a new
tuneable positive and negative selection for evolution of
orthogonal translational machinery. The selection methods are
applied to evolving multiple orthogonal ribosome mRNA pairs
(O-ribosome O-mRNA). Also described is the successful prediction of
the network of interactions between cognate and non-cognate
O-ribosomes and O-mRNAs. Knowledge of the specificity of these
molecular interactions permits programming of post-transcriptional
Boolean logic in cells.
[0051] Positive-Negative Selection Approach:
[0052] A selection approach for the identification of orthogonal
ribosome orthogonal mRNA pairs, or other pairs of orthogonal
molecules, entails a concerted use of positive and negative
selection. In one aspect, for example, negative selection is used
to remove from a library of mRNA sequences those members that are
substrates for wild-type ribosomes, and positive selection is used
to select from a library of mutated ribosomes those that
efficiently translate the remaining mRNAs that are not translated
by the wild-type ribosomes.
[0053] A number of different positive and negative selection agents
can be used. Ideal positive and negative selections in, for
example, E. coli would be tuneable in response to two small
molecules (one for each selection) over a large dynamic range.
Several positive selections have been used in E. coli , the most
common of which involve conditional survival on antibiotics. Of
these positive selections, the chloramphenicol acetyl-transferase
gene in combination with the antibiotic chloramphenicol has proved
one of the most useful. Others as known in the art, such as
ampicillin, kanamycin, tetracycline or streptomycin resistance,
among others, can also be used.
[0054] Negative selections in, for example, E. coli have used the
ribonuclease bamase. However, barnase is both extremely toxic and
constitutively active, which limits its utility in tuneable
selections for the isolation of a range of activities. Perhaps the
most widely used negative selection in, for example, gram negative
bacteria uses the Bacillus subtilis sacB gene, which converts
saccharose into levan sucrase and confers sucrose sensitivity on
the cell. The selection, however, requires the forced uptake of
sucrose by the addition of huge extracellular concentrations (5% or
more). The stress of this procedure is believed to lead to
mutations that bypass the stringency of the selection; while in
principle the selection is tuneable, in practice such high
concentrations of sucrose are required that the dynamic range is
low (Galvao, T. C. & de Lorenzo, V., Appl Environ Microbiol 71,
883-892 (2005)). A. novel, and likely tuneable negative selection
involves uracil phosphoribosyltransferase (UPRT) (Galvao, T. C.
& de Lorenzo, V., Appl Environ Microbiol 71, 883-892 (2005),
Rasmussen, U. B., Mygind, B. & Nygaard, P., Biochim Biophys
Acta 881, 268-275 (1986)). This enzyme operates in the nucleotide
salvage pathway to convert uracil into uridine monophosphate, the
source of all pyrimidine nucleoside triphosphates in the cell. If
5-fluorouracil is added to cells, it is converted to 5fluoro-dUMP
by UPRT which strongly inhibits thymidylate synthase (Neuhard, J.
in Metabolism of Nucleotides, Nucleosides, and Nucleobases in
Microorganisms. (ed. O. Munch-Petersen) 95-148 (Academic Press, New
York, NY, N.Y.; 1983)), and leads to cell death.
[0055] Selection of O-ribosome O-mRNA pairs is facilitated by a
single transcript that can respond to either a positive or a
negative selection depending on the identity and dose of a small
molecule added to the media (FIG. 2a). One way to do this is to
generate a single construct encoding a fusion polypeptide that
comprises both the positive and negative selectable marker
activities. The generation of fusion constructs is well known in
the art. Positive and negative selectable markers as known in the
art can be used in such a construct. As discussed above with
respect to the markers themselves, the selectable markers will
ideally each have a dynamic range that permits tuning the
stringency of the selection to obtain a broader spectrum of
selected mutant activity. The dynamic range for selectable markers
is preferably at least two fold, more preferably at least 5-fold,
10-fold, 50-fold, 100- fold, 500-fold or more. One of skill in the
art can determine the dynamic range of a given selectable marker
and its corresponding selection agent using, for example, an
approach as described in the Examples herein. The decision of which
selectable marker polypeptide to place N-terminal and which to
place C-terminal in the construct can be empirical because there
are only two choices for a given combination of two markers.
However, where aspects of the structures and, for example, their
sensitivities to alteration or steric hindrances, are known, those
considerations can dictate which of the two orientations is most
likely to work. Where necessary, short peptide linkers as known in
the art can be used to space the two fused selectable markers apart
sufficiently to preserve both selectable functionalities. Further,
the Examples below describe methods useful to ascertain the
function of both selectable marker polypeptides in the context of a
fusion protein.
[0056] The methods described herein and exemplified in the Examples
below permit the evolution of highly active and highly specific
orthogonal ribosome mRNA pairs by gene duplication followed by a
novel positive and negative selection. These pairs can be used, for
example, to produce a transcript in a host cell that can only be
translated by the cognate orthogonal ribosome, thereby permitting
extremely sensitive control of the expression of a polypeptide
encoded by the transcript. The pairs can thus be used to produce a
polypeptide of interest by, for example, introducing nucleic acid
encoding such a pair to a cell, where the orthogonal mRNA encodes
the polypeptide of interest. The translation of the orthogonal mRNA
by the orthogonal ribosome results in production of the polypeptide
of interest. It is contemplated that polypeptides produced in cells
encoding orthogonal mRNA orthogonal ribosome pairs can include
unnatural amino acids.
[0057] Unlike the progenitor ribosome in natural cells, orthogonal
ribosomes are not responsible for synthesizing the proteome, and it
will therefore be possible to further diverge their function. For
example, it may be possible to produce ribosomes that decode
extended codons (Magliery, T. J., Anderson, J. C. & Schultz, P.
G., J Mol Biol 307, 755-769 (2001), Anderson, J. C., Magliery, T.
J. & Schultz, P. G., Chem Biol 9, 237-244 (2002)), with greater
efficiency and specificity, or specifically decode only a subset of
natural codons. Each of these ribosomes would have applications for
further expanding or altering the genetic code.
[0058] The methods described herein are applicable to the selection
of orthogonal mRNA orthogonal rRNA pairs in species in which base
pairing between ribosomal RNA and a ribosome binding sequence on
mRNA occurs during the initiation of translation. Thus, the methods
are broadly applicable across bacteril species, in which this
mechanism is conserved. The sequence of 16S rRNA is known for a
large number of bacterial species and has itself been used to
generate phylogenetic trees defining the evolutionary relationships
between the bacterial species (reviewed, for example, by Ludwig
& Schleifer, 1994, FEMS Microbiol. Rev. 15: 155-73; see also
Bergey's Manual of Systematic Bacteriology Volumes 1 and 2,
Springer, George M. Garrity, ed.). The Ribosomal Database Project
II (Cole J R, Chai B, Farris R J, Wang Q, Kulam S A, McGarrell D M,
Garrity G M, Tiedje J M, Nucleic Acids Res, (2005) 33 (Database
Issue):D294-D296. doi: 10.1093/nar/gki038) provides, in release
9.28 (June 17, 2005 ), 155,708 aligned and annotated 16S rRNA
sequences, along with online analysis tools.
[0059] Phylogenetic trees, such as that shown in FIG. 6 are
constructed using, for example, 16S rRNA sequences and the neighbor
joining method in the ClustalW sequence alignment algorithm. Using
a phylogenetic tree, one can approximate the likelihood that a
given set of mutations (on 16S rRNA and corresponding translation
control sequence on an mRNA) that render the set orthogonal with
respect to each other in one species will have a similar effect in
another species. Thus, the mutations rendering mRNA/16S rRNA pairs
orthogonal with respect to each other in one member of, for
example, the Enterobacteriaceae Family (e.g., E. coli) would be
more likely to result in orthogonal mRNA/orthogonal ribosome pairs
in another member of the same Family (e.g., Salmonella) than in a
member of a different Family on the phylogenetic tree.
[0060] In some instances, where bacterial species are very closely
related, it may be possible to introduce corresponding 16S rRNA and
mRNA mutations that result in orthogonal molecules in one species
into the closely related species to generate an orthogonal mRNA
orthogonal rRNA pair in the related species. Also where bacterial
species very are closely related (e.g., for E. coli and Salmonella
species), it may be possible to introduce orthogonal 16S rRNA and
orthogonal mRNA from one species directly to the closely related
species to obtain a functional orthogonal mRNA orthogonal ribosome
pair in the related species.
[0061] Alternatively, where the species in which one wishes to
identify orthogonal mRNA orthogonal ribosome pairs is not closely
related (e.g., where they are not in the same phylogenetic Family)
to a species in which a set of pairs has already been selected, one
can use positive-negative selection methods as described herein to
generate orthogonal mRNA orthogonal ribosome pairs in the desired
species. Briefly, one can prepare a library of mutated ribosome
binding sequences linked to a sequence encoding a positive-negative
selection fusion polypeptide as described herein (the bacterial
species must be sensitive to the activity of the selection agents,
a matter easily determined by one of skill in the art). The library
can then be introduced to the chosen species, with selection
against mRNAs that are substrates for wild-type ribosomes. A
library of 16S rRNA sequences can be generated by mutating the 16S
rRNA of the chosen species. The mutant 16S rRNA library can then be
introduced to cells comprising the mRNAs that are not substrates
for wild-type ribosomes, followed by positive selection for those
cells expressing the positive selectable marker in order to
identify orthogonal ribosomes that pair with the mRNAs selected in
the first selection.
[0062] Ribosome binding sequences can and do differ in different
species, although a region of complementarity to a region of
corresponding 16S rRNA is maintained. Two approaches can be taken
where there is not necessarily a known consensus ribosome binding
sequence for a given species. In one approach, the sequences
surrounding or adjacent to the translation start codon of a model
transcript in that species, such as one for a housekeeping or other
gene, can be used to generate the first library of mutated mRNA
sequences--that is, the translation-regulatory sequences of a
single transcript can be used to generate a mutated library of
translation regulatory sequence linked to a positive-negative
reporter as described herein. Negative and positive selection along
with a library of mutant 16S rRNA sequences as described above will
permit the isolation of orthogonal mRNA orthogonal ribosome pairs
based on the members of the mutant translation regulatory sequence.
In the other approach, mRNA sequences from the chosen species can
be aligned with each other and with the region of 16S rRNA expected
(based on similarities to E. coli 16S rRNA or other 16S rRNA for
which the mRNA-interacting sequences are known) to base pair with
the ribosome binding site using any of a number of different
algorithms. The alignment permits the identification of conserved
sequences most likely tointeract with the 16S rRNA, thereby
permitting the selection of a consensus for that species. An mRNA
library diversified in that consensus region can then be generated
to provide starting material for selection of orthogonal mRNA
orthogonal ribosome pairs functional in that species as described
herein.
[0063] The methods described herein are applicable to the
identification of molecules useful to control translation or other
processes in a wide range of bacteria, including bacteria of
industrial and agricultural importance as well as pathogenic
bacteria. Pathogenic bacteria are well known to those of skill in
the art, and sequence information, including not only 16S rRNA
sequence, but also numerous mRNA coding sequences, are available in
public databases, such as GenBank. Common, but non-limiting
examples include, e.g., Salmonella species, Clostridium species,
e.g., Clostridium botulinum and Clostridium perfringens,
Staphylococcus sp., e.g, Staphylococcus aureus; Campylobacter
species, e.g., Campylobacter jejuni, Yersinia species, e.g.,
Yersinia pestis, Yersinia enterocolitica and Yersinia
pseudotuberculosis, Listeria species, e.g., Listeria monocytogenes,
Vibrio species, e.g., Vibrio cholerae, Vibrio parahaemolyticus and
Vibrio vulnificus, Bacillus cereus, Aeromonas species, e.g.,
Aeromonas hydrophila, Shigella species, Streptococcus species,
e.g., Streptococcus pyogenes, Streptococcus faecalis, Streptococcus
faecium, Streptococcus pneumoniae, Streptococcus durans, and
Streptococcus avium, Mycobacterium tuberculosis, Klebsiella
species, Enterobacter species, Proteus species, Citrobacter
species, Aerobacter species, Providencia species, Neisseria
species, e.g., Neisseria gonorrhea and Neisseria meningitidis,
Heamophilus species, e.g., Haemophilus influenzae, Helicobacter
species, e.g., Helicobacter pylori, Bordetella species, e.g.,
Bordetella pertussis, Serratia species, and pathogenic species of
E. coli , e.g., Enterotoxigenic E. coli (ETEC), enteropathogenic E.
coli (EPEC) and enterohemorrhagic E. coli O157:H7 (EHEC).
[0064] Bacterial transformation:
[0065] The methods described herein rely upon the introduction of
foreign or exogenous nucleic acids into bacteria. Methods for
bacterial transformation with exogenous nucleic acid, and
particularly for rendering cells competent to take up exogenous
nucleic acid, is well known in the art. For example, Gram negative
bacteria such as E. coli are rendered transformation competent by
treatment with multivalent cationic agents such as calcium chloride
or rubidium chloride. Gram positive bacteria can be incubated with
degradative enzymes to remove the peptidoglycan layer and thus form
protoplasts. When the protoplasts are incubated with DNA and
polyethylene glycol, one obtains cell fusion and concomitant DNA
uptake. In both of these examples, if the DNA is linear, it tends
to be sensitive to nucleases so that transformation is most
efficient when it involves the use of covalently closed circular
DNA. Alternatively, nuclease-deficient cells (RecBC strains) can be
used to improve transformation.
[0066] Electroporation is also well known for the introduction of
nucleic acid to bacterial cells. Methods are well known, for
example, for electroporation of Gram negative bacteria such as E.
coli , but are also well known for the electroporation of Gram
positive bacteria, such as Enterococcus faecalis, among others, as
described, e.g., by Dunny et al., 1991, Appl. Environ. Microbiol.
57: 1194-1201.
[0067] The positive-negative selection approach described herein
for the selection of orthogonal ribosome orthogonal mRNA pairs can
be applied to the selection of additional pairs of orthogonal
molecules. For example, orthogonal promoter/polymerase pairs can be
identified by application of the positive-negative selection
approach described herein. By analogy to the methods described
herein for selection of orthogonal ribosome orthogonal mRNA pairs,
one can generate a library of promoters and screen using negative
selection (e.g., 5-FU/UPRT selection) for promoters that are not
transcribed by endogenous polymerases, or, for that matter, a
desired exogenous polymerase expressed in that cell. One can then
transform the negative-selected cells with a library encoding
mutant polymerase and subject the cells to positive selection for
those that express the positive selectable marker (e.g., CAT) from
a mutant promoter selected in the first step. The result is a
mutant promoter that is not recognized by wild-type polymerases and
a polyrnerase that specifically recognizes that mutant promoter.
Together they constitute a very specific means of gene
regulation.
[0068] A similar approach can be taken to the selection of, for
example, riboswitches or riboregulators. A "riboswitch" is an mRNA
structure that can fold in the presence of a metabolite or other
small molecule or ion to regulate translation by altering mRNA
conformation. Thus, riboswitches are structured domains in the
non-coding portions of some mRNAs that sense the presence of a
metabolite. Metabolite binding causes allosteric changes in the
mRNA that result in changes in processes such as translation
initiation or translation termination. Riboswitches are further
described in Mandal & Breaker, 2004, Nat. Rev. Mol. Cell. Biol.
5:451-63. Using a positive-negative selection approach as described
herein, one can, for example, select from an mRNA library those
sequences able to bind small molecules and up- or down-regulate
gene expression. This can be accomplished, for example, by placing
a library of mRNA sequences 5' of the SD sequence and identifying
those sequences that inactivate translation for the SD sequence
(5-FU/UPRT selection). The small molecule is then added, with
selection for re-activation of translation by positive selection. A
reciprocal approach can be taken to provide small molecule
repressors of gene expression.
[0069] A "riboregulator" is a small RNA that regulates gene
expression. "Riboregulators" are described in, for example, Eddy,
1999, Curr. Opin. Genet. Dev. 1999 9:695-9 and Lease et al., 1998,
Proc. Natl. Acad. Sci U.S.A. 95:12456-61. By replacing the small
molecule in the riboswitch example above with the expression of a
small non-coding RNA, one can identify riboregulator RNAs that
activate or repress mRNA translation.
[0070] Positive-negative selection can also be used to identify
modified transcription factor/transcription factor binding site
pairs. In this approach, a known transcription factor binding site
can be altered, in the most extreme cases to completely random
sequence. Sequences that do not lead to transcription with the
wild-type factor are selected by negative selection with 5-FU/UPRT.
A library of mutant transcription factors is then introduced, with
positive selection for the activation of transcription from the
active site that leads to expression f the positive selectable
marker, e.g., CAT.
EXAMPLES
Example 1
Generation and Testing of a Positive-Negative Selectable Marker
Fusion Construct.
[0071] A genetic fusion was generated between the chloramphenicol
acetyl-transferase (cat) gene and the uracil
phosphoribosyltransferase (upp) gene, downstream of a constitutive
promoter and wild type ribosome-binding site, on a p15A derived
vector (maintained at 10-15 copies per cell). Both CAT and UPRT
function as trimers, but whereas the CAT trimer has been
crystallized (Leslie, A. G., J Mol Biol 213, 167-186 (1990)), the
UPRT trimer has an unknown structure and symmetry (Rasmussen, U.
B., Mygind, B. & Nygaard, P., Biochim Biophys Acta 881, 268-275
(1986)). The correct linkage to produce both activities in a single
polypeptide was therefore unknown. However, it has previously been
observed that CAT is sensitive to fusions to its N terminus, and on
this basis it was decided to create a cat-upp fusion.
[0072] P21, a vector expressing a CAT-UPRT fusion, has a p15A
origin of replication, a cat-upp fusion downstream of a
constitutive version of the Trp promoter, and a tetracycline
resistance marker. All Bsa I restriction sites have been removed to
allow enzymatic inverse PCR mutagenesis (Yusupova, G. Z., Yusupov,
M. M., Cate, J. H. & Noller, H. F., Cell 106, 233-241 (2001))
or library construction with the vector as a template. The plasmid
was created in several steps using standard molecular biology
methods (plasmid map available below). Enzymatic inverse PCR (as
described in detail for library construction) was used to construct
P23, the promoterless cat-upp fusion, and P24, a start codon
deleted cat-upp fusion using p21 as a template. The complete
sequence of the oligonucleotides used to construct these vectors
can be found below.
[0073] To establish that both CAT and UPRT were functionally
expressed from the cat-upp fusion, and to measure the dynamic range
of each selection, two constructs were created. One construct
constitutively expresses the cat-upp fusion, and is a maximum
translation control, and the other construct .DELTA.pcat-upp has
the entire promoter of the cat-upp fusion deleted and is a minimum
translation control. When transformed into a strain of E. coli
(GH371), containing an ORF deletion of genomic upp, the cat-upp
fusion allowed cells to survive on chloramphenicol concentrations
of 150 .mu.g ml.sup.-1, while .DELTA.pcat-upp only led to
chloramphenicol resistance at concentrations between 5 .mu.g
ml.sup.-1 and 10 .mu.g ml.sup.-1 (FIG. 2b). These experiments
demonstrate that CAT is produced in a functional form from the
cat-upp fusion and the dynamic range of this positive selection is
15-fold.
[0074] To ascertain if UPRT was active in the cat-upp fusion and to
assess the dynamic range of the 5-FU mediated negative selection
the survival of cells containing cat-upp/GH371 and
.DELTA.pcat-upp/GH371 was measured on increasing concentrations of
5-FU. Cat-upp/GH371 died on 5-FU concentrations of 0.5 .mu.g
ml.sup.-1 while .DELTA.pcat-upp/GH371 survived on 5-FU up to 20
.mu.g ml.sup.-1. These experiments demonstrate that UPRT is
produced in a functional form from the cat-upp fusion and the
dynamic range of this negative selection is 50-fold (FIG. 2b). The
survival spectrum of .DELTA.pcat-upp/GH371 on Chloramphenicol or
5FU was indistinguishable from the survival of .DELTA./GH371 ( is a
plasmid in which the entire cat-upp ORF is deleted) demonstrating
that there is no measurable read through of the cat-upp ORF derived
from leaky transcription of other plasmid encoded genes.
[0075] Model enrichment studies were performed to examine the
potential of the system for selecting orthogonal SD sequences that
are not substrates for the endogenous ribosome, and for selecting
complementary ribosomes. These model selections are summarized in
Table 1, below.
TABLE-US-00001 TABLE 1 Model Selections A. Model Selections for
functional ribosome mRNA pair Starting Ratio.sup.a 1:50 1:500 1:5
.times. 10.sup.3 1:5 .times. 10.sup.4 1:5 .times. 10.sup.5 1:5
.times. 10.sup.6 Cell 10.sup.-4 10.sup.-5 10.sup.-3 10.sup.-4
10.sup.-2 10.sup.-3 10.sup.-1 10.sup.-2 neat 10.sup.-1 neat
10.sup.-1 dilution cm.sup.R b(+P.sup.c) 199 28 226 25 191 18 229 21
148 27 20 2 (100) (100) (100) (100) (100) (100) Enrichment >50
>500 >5 .times. 10.sup.3 >5 .times. 10.sup.4 >5 .times.
10.sup.5 >5 .times. 10.sup.6 Factor B. Model Selections for
non-functional ribosome mRNA pair Starting Ratio.sup.a 1:10 1:100
1:10.sup.3 1:10.sup.4 Cell 10.sup.-4 10.sup.-5 10.sup.-3 10.sup.-4
10.sup.-2 10.sup.-1 10-.sup.2 10.sup.-1 Dilution Not 5FU.sup.Sd 51
2 62 9 53 8 10 1 (.DELTA.P.sup.e) (100) (100) (100) (100)
Enrichment >10 >100 >1 .times. 10.sup.3 >1 .times.
10.sup.4 factor .sup.aCalculated from colony forming units (c.f.u.)
of the .DELTA.Promoter and + Promoter clones on media containing 25
.mu.g ml.sup.-1, tetracycline, without chloramphenicol or 5-FU,
prior to mixing. .sup.bApproximately 10.sup.8 c.f.u. were plated.
.sup.cThe percentage of these clones with a promoter (10
characterized by colony PCR and sequencing). .sup.dApproximately
10.sup.6 c.f.u. were plated. .sup.eThe percentage of these clones
without a promoter (10 characterized by colony PCR and
sequencing).
[0076] In the first selection the enrichment of an inactive
ribosome mRNA pair from a vast excess of active ribosome mRNA pairs
was modeled. .DELTA.pcat-upp/GH371 were mixed with a 10 to 10.sup.4
fold excess of cat-upp/GH371 and the mixture selected on 0.5 .mu.g
ml.sup.-1 5-FU. The ratio of cells surviving to the total number of
cells plated correlates well with the ratio of .DELTA.pcat-upp to
cat-upp without selection. Colony PCR confirmed that 100% of the
selected clones were .DELTA.pcat-upp. These experiments demonstrate
that the UPRT based negative selection allows the enrichment of
clones that are not substrates for the endogenous ribosome from a
greater than 10.sup.4 fold excess of mRNA sequences that are
substrates for the endogenous ribosome.
[0077] In a second selection the enrichment of active ribosome mRNA
pairs from a vast excess of inactive ribosome mRNA pairs was
modeled (Table 1). cat-upp/GH371 were mixed with a 10- to 10.sup.6
fold excess of cells containing .DELTA.pcat-upp/GH371. The ratio of
cells surviving on 100 .mu.g ml.sup.-1 chloramphenicol to the total
number of cells plated correlates well with the ratio of
cat-upp/GH371 to .DELTA.pcat-upp/GH371 without selection, and
colony PCR confirmed that the selected clones were cat-upp. These
experiments demonstrate that the CAT based positive selection can
enrich active ribosome mRNA pairs from greater than 10.sup.5 fold
excess of non-functional pairs.
Example 2
Design and Construction of SD ASD Libraries
[0078] A) mRNA library:
[0079] Analysis of the genome-wide variation in sequence 5' to AUG
initiation codons has demonstrated that the highest information
content for ribosome binding is between -7 and -13, with the
information that specifies ribosome binding partitioned across this
sequence differently for different sequences in the genome
(Shultzaberger, R. K., Bucheimer, R. E., Rudd, K. E. &
Schneider, T. D., J Mol Biol 313, 215-228 (2001)). A library was
designed that mutates all seven nucleotides from -7 to -13 to all
possible sequence combinations (FIG. 3a). This library contains all
potential five base SD sequences, including those sequences that
contain wild-type bases, giving a theoretical diversity of
4.sup.7=16,384. In addition it allows the region of base pairing
with the ribosome to vary in register with respect to the start
codon.
[0080] The mRNAlib was created by enzymatic inverse PCR using the
primers 5'- GGGAAAGGTCTCCCGCTTTCANNNNNNNCCGCAAATGGAGAAAAAAATCACTGG
ATATACC-3' (SEQ ID NO: 3) and 5'-
GGAGTAGGTCTCAAGCGGCCGCTTCCACACATTAAACTACTAGTTC-3' (SEQ ID NO: 4)
and p21 as template. Reactions contained: 20 pmol forward primer,
20 pmol reverse primer, 10 ng template plasmid, 40 pmol dNTPs, 1 x
Expand buffer 2 (Roche), in a total volume of 49.5 .mu.l 1.75 U
Expand High Fidelity DNA polymerase (Roche, 3.5 U .mu.l.sup.-1) was
added to the reaction at 80.degree. C. Reactions were cycled in
touchdown PCR (94.degree. C., 20 s; 65.degree. C., 20 s (-1.degree.
C. cycle.sup.-1); 68.degree. C., 8 min) for 20 cycles, followed by
amplification (94.degree. C, 20 s; 50.degree. C., 20 s; 68.degree.
C., 8 min) for 20 cycles. The resulting PCR product (5 .mu.g) was
purified (Qiagen PCR purification), digested (Dpn I (40 U, 6 h);
Bsa I (50 U, 6h), re-purified (Qiagen PCR purification), ligated
(T4 DNA ligase (16.degree. C., 12 h), ethanol precipitated, and
transformed by electroporation into DH10B electrocompetent cells.
Plasmid DNA was isolated and retransformed into GH371 cells for
selections. This strain (a generous gift from J. Christopher
Anderson, UCSF) is a derivative of GeneHogs E. coli in which the
upp ORF is completely deleted. Similar strains having the
non-functional upp ORF can be generated in a straightforward manner
using gene knockout methods well known in the art. Alternatively,
upp mutants can be selected as necessary, for example, by exposing
E. coil strains to low doses of 5-FU and selecting for surviving
cells that spontaneously down-regulate the upp gene.
[0081] The mRNAlib library realizes greater than 10.sup.7
independent transformants, providing greater than 99.99%
confidence, as determined from a Poisson distribution (Ladner, R.
C. in Phage Display of Peptides and Proteins. (eds. B. K. Kay, J.
Winter & J. McCafferty) 151-194 (Academic Press, San Diego;
1996)), that the library is complete. To determine the fraction of
mRNAlib clones that are substrates for the endogenous ribosome
GH371 cells transformed with mRNAlib were plated on agar plates
containing no chloramphenicol, and on agar plates containing
chloramphenicol at a concentration just sufficient to kill
untransformed cells (10 .mu.g/ml.sup.-1). 50% of cells survive on
10.mu.g ml .sup.-1, suggesting that approximately half the library
is translated to some extent by endogenous ribosomes. Since the
theoretical diversity of the library is 16,384, and sequencing
reveals no significant bias in its nucleotide composition,
approximately 8,000 distinct sequences are not translated by the
endogenous ribosome and are potentially orthogonal.
[0082] B) rRNA library:
[0083] To create the ribosomal RNA library (rRNAlib) eight
nucleotides in the 16S rRNA (FIG. 3a,b) were mutated. Six of these
nucleotides are in the region from 1536-1541 at the 3' end of the
16S rRNA. Five of these bases pair with the mRNA in the classic SD
ASD (Yusupova, G. Z., Yusupov, M. M., Cate, J. H. & Noller, H.
F., Cell 106, 233-241 (2001)), interaction and are clearly
important determinants of translational efficiency on endogenous
mRNAs, whereas the sixth allows additional flexibility in the
spacing between the SD and the ribosomal A site. The final two
mutated bases, 722 and 723, form a bulge proximal to the minor
groove of the SD helix formed between the ribosome and mRNA
(Yusupova, G. Z., et al., Supra). 722 forms a non-canonical G-G
base pair with nucleotide 767. 723 is unpaired and comes close to
the minor groove of the SD helix, but in the 5 .ANG. structure
showing the path of the mRNA through the ribosome (Yusupova, G. Z.,
et al., Supra), the molecular details of any interaction.between
the 723 bulge and the SD helix are undefined. These mutations
acknowledge the possibility that the 723 bulge might monitor the
geometry of the minor groove of the SD helix, and explore the
possibility that mutations at these positions might allow access to
an expanded set of functional SD ASD sequences.
[0084] The plasmids for rRNA library construction are derivatives
of pSP72 and pSP73 (Promega), from which Bsa I and Pst I sites were
removed, and new Pst I and NgoM IV sites engineered in the
.beta.-lactamase gene. The E. coli rrnB 23S-containing fragment was
subcloned into the pSP73 derivative as an Xba I, BamH I fragment
from pSTL102 (A generous gift from Professor Harry Noller,
University of California, Santa Cruz) yielding the plasmid pJC23S.
The E. coli rrnB 16S fragment was amplified from pSTL102 with Cla I
and Xba I flanking sequence and cloned into the pSP72 derivative
using Cla I and Xba I, yielding pJC16S. Plasmid maps of pJC23S and
pJC16S are available below. For expression of mutant rRNA
sequences, a derivative of pTrcHis2 A (Invitrogen) was constructed,
designated pTrc.DELTA.Kan. A plasmid map of pTre.DELTA.Kan can be
found below.
[0085] The rRNAlib library of 16S rRNA mutants was generated by two
rounds of enzymatic inverse PCR each followed by Dpn I, Bsa I
digestion, ligation and transformation, as described for the
construction of mRNAlib. This was followed by operon assembly with
the 23S/5S fragment from pJC23S and transfer of the complete operon
to a promoter. To construct the library at the 3' end of the 16S
rRNA, pJC16S was used as a template with oligonucleotides 5'-
GGAAAGGTCTCAGGTTGGATCANNNNNNTACCTTAAAGAAGCGTACTTTGTAG-3' (SEQ ID
NO: 5) and 5'-GAGTAGGTCTCAAACCGCAGGTTCCCCTACG-3' (SEQ ID NO: 6).
The resulting library was used as a template for the randomization
of the nucleotides at positions 722 and 723 using the
oligonucleotides 5'-
GGAAAGGTCTCAGAATACCGNNGGCGAAGGCGGCCCCCTGGACGAA-3' (SEQ ID NO: 7)
and 5'-GAGTAGGTCTCAATTCCTCCAGATCTCTACGCATTTCAC-3' (SEQ ID NO: 8).
16S rRNA mutant libraries in the pJC16S backbone were assembled
with the 23S and 5S rRNA containing fragment in pJC23S by Pst I,
Xba I subcloning of gel purified DNA fragments. The.resulting
pJC16S23S plasmid contains the library of rrnB rRNA operons. These
were transferred to the pTrc.DELTA. expression plasmid by BamH I,
Nde I and Xho I digestion of pJC16S23S, and BamH I, Stu I, and Xho
I digestion of pTrc.DELTA.Kan. The resulting BamH I, Xho I
fragments were gel purified and subcloned to create rRNAlib.
[0086] The library makes no assumptions about the nucleotide
composition of the eight mutated nucleotides and allows all four
bases at each of the eight positions giving a theoretical diversity
of 4.sup.8=65,536. Greater than 10.sup.7 independent transformants
of rRNAlib were realized providing greater than 99.99% confidence
that the library is complete as calculated by Poisson sampling,
(Ladner, R.C., Supra).The unique pairs of mRNAlib and rRNAlib
library members form a matrix of greater than 10.sup.9
combinations.
Example 3
Selection and Characterization of Orthogonal Ribosome mRNA
Pairs
[0087] To interrogate the matrix for O-ribosome O-mRNA combinations
a two-step approach was taken. In the first step mRNA sequences
that are not translated by endogenous ribosomes were screened for.
To remove mRNAlib members that are substrates for endogenous
ribosomes, a negative selection was performed by growing the
ribosome binding site library in the presence of 5-FU. Active
ribosome binding sites direct the synthesis of the cat-upp fusion,
and UPRT protein converts 5FU to a toxic product, poisoning the
cell. In contrast ribosome-binding sites that are not substrates
for the endogenous ribosome do not direct the synthesis of UPRT and
survive the selection. The library is therefore selectively
enriched in O-mRNAs. Ten clones from this first selection were
sequenced at random. Ten distinct sequences were observed at this
point, suggesting the library is still quite diverse, as expected
from the previous observation that half of the mRNAlib library is
not a substrate for the endogenous ribosome prior to 5FU
selection.
[0088] In a second step, ribosomes were screened for that translate
the selected orthogonal mRNAs. Cells containing the selected
ribosome binding sites were transformed with the library of mutant
ribosomes, yielding 10.sup.11 transformants, over-sampling the
total theoretical diversity of ribosome mRNA combinations by two
orders of magnitude. The library was grown in the presence of
chloramphenicol, and active ribosome O-mRNA pairs selected. In this
selection only for pairs with comparable activity to the wild-type
pair were sought. Under lest stringent conditions it may be
possible to isolate less highly active, but still active ribosome
mRNA pairs.
[0089] The methods used for the selections are detailed briefly
below. GH371 E. coli were transformed with mRNAlib, then recovered
for 1 h in SOC. The library was then plated on selective media
(M9agar containing 0.4% glucose, 0.2% casaminoacids, 25 .mu.g
ml.sup.-1 tetracycline, 0.5 .mu.g ml.sup.-1 5-FU). After 24 h,
surviving cells were pooled and used to prepare electrocompetent
GH371/mRNAlib(-)cells.
[0090] GH371/mRNAlib(-) cells were transformed with the rRNAlib
library, and recovered for 1 h in SOB containing 2% glucose. The
recovered cells were used to inoculate 200 ml of LB-GAT (LB media
supplemented with 2% v/v glucose, 100 .mu.g ml.sup.-1 ampicillin,
25 .mu.g ml.sup.-1 tetracycline), grown to saturation, and pelleted
by centrifugation at 3000 g. The cells were resuspended in LB-AT
((LB media supplemented with 100 .mu.g ml .sup.-1 ampicillin, 25
.mu.g ml.sup.-1 tetracycline) and incubated (37.degree. C., 300
rpm, 1 h) before pelleting at 3000 g. Cells were resuspended in an
equal volume of LB-ATI (LB medium containing 25 .mu.g ml.sup.-1
ampicillin and 7.5 .mu.g ml.sup.-1 tetracycline, 1 mM
isopropyl-D-thiogalactopyranoside (IPTG)) and incubated (37.degree.
C., 300 rpm, 3.5 h). 1 ml aliquots (OD.sub.600=1) were plated on LB
ATI agar supplemented with 100 .mu.g ml.sup.-1 chloramphenicol and
incubated (16 h, 37.degree. C.).
[0091] Total plasmid DNA was isolated from selected clones. To
purify rRNAlib members from their cognate mRNAlib members and vice
versa a fraction of each plasmid sample was digested with
restriction enzymes that recognize sites found only in rRNAlib (Bsa
I) or in the mRNAlib (Not I) and the digests re-transformed into
GH371. Individual transformants were replica plated on ampicillin
and tetracycline to confirm the separation. Plasmid DNA was
isolated and sequenced by standard methods.
[0092] Competent GH371/mRNAlib clones were transformed in parallel
with either pTrc-WT (encoding rRNA from the rrnB operon) or the
corresponding rRNAlib member. Cells were recovered in SOB with 2%
glucose and transferred to LB GAT and grown overnight at 200 rpm.
Cells (100 .mu.l) were transferred to each well of a 96 well
culture block and pelleted by centrifugation at 3000 g. Cells were
resuspended in 1 ml LB AT, incubated (37.degree. C., 300 rpm, 1. h)
and then pelleted at 3000 g. They were resuspended in an equal
volume of LB ATI and incubated (37.degree. C., 300 rpm, 3.5 h),
before being arrayed using a 96 well pin tool on LB ATI agar
containing chloramphenicol at concentrations from 0 to 100 .mu.g
ml.sup.-1. To measure the interactions that form the ribosome mRNA
network between the three orthogonal ribosomes and mRNAs, assays
were repeated with cognate and non-cognate ribosome mRNA pairs.
[0093] From the two-step selection, 51 individual ribosomal RNAs
and the corresponding O-mRNAs were sequenced (FIG. 4a). Four
distinct O-mRNAs were discovered (FIG. 4a), with two of the four
isolated sequences containing non-programmed deletions in the
mutagenized region. Since sequencing of ten clones after the
negative selection returned 10 distinct sequences, and the
diversity was estimated at that stage to be approximately 8,000, it
is concluded that the positive selection led to a significant
(.about.2,000-fold) convergence in the mRNA sequences. These
results highlight the advantages of selection methods for finding
O-ribosome O-mRNA pairs. While it may be relatively simple to find
mRNA SD sequences that do not function with the endogenous ribosome
(for example by altering the mRNA sequence to remove base pairing
with the 16S rRNA) there are no highly active, non-toxic ribosomes
to complement the vast majority of these mRNA sequences and the
chance of picking a mRNA sequence that can be complemented is very
low.
[0094] Ten distinct ribosomes with complementarity to the O-mRNAs
were discovered (FIG. 4a). The mutations in the 16S rRNA of the
selected ribosomes are highly convergent at several positions. At
position 1536, U (59%) dominates. At position 1537, G is very
strongly selected (90%). Position 1539 contains solely purines: A
(69%) or G (31%), and position 1540 is dominated by G (73%). The
wild type residues are selected with a reasonable frequency at some
positions: 1535C is recovered in 13% of sequences, and 1538C in 51%
of sequences. The sequence conservation at positions 722 and 723 in
the selected clones is low. However, purines and pyrimidines are
mutually exclusive at these positions in a given selected sequence,
and this may reflect a selection constraint that conserved the
volume occupied by this loop.
[0095] Ten pairs of cognate ribosome mRNA sequences were identified
in this initial screen (FIG. 4b). Each mRNA has an IC.sub.50 of 10
.mu.g ml.sup.-1 or less on chloramphenicol in the absence of its
cognate ribosome, and is therefore orthogonal (O-mRNA) with respect
to the endogenous ribosome. Addition of the co-selected ribosome
increases the IC.sub.50 to greater than or equal to 150 .mu.g
ml.sup.-1 in all cases. The co-selected ribosomes are therefore
highly active, and translate the message from the O-mRNA as well or
better than the endogenous ribosome translates the same message
from a classic SD sequence. The ten pairs fall into three classes
on the basis of predicted SD ASD base pairing, with each class
forming a SD ASD interaction over exactly 5 base pairs. The first
class of pairs contains the bases ACCAC -6 (SEQ ID NO: 9; numbering
refers to position of 3' base) to AUG in the mRNA. This is
complemented by four distinct ribosomes that can Watson-Crick pair
with the mRNA over five bases. Two distinct registers of the 16S
rRNA with respect to the SD sequence are observed. In the first
register, exemplified by rRNA-1, bases 1536 to 1540 of the 16S rRNA
Watson-Crick pair with mRNA-A. In the second register, exemplified
by pairs A2, A3, and A4, bases 1537 to 1541 of the 16S rRNA
Watson-Crick pair with the cognate mRNAs. Pyrimidines are favored
in the selected sequences at the two positions immediately 5' to
the region of the rRNA that Watson-Crick base pairs with the mRNA.
A second class of pairs (B5, B6, B7, B8) contain the sequence ACUGC
-7 (SEQ ID NO: 10) to AUG in the O-mRNA. The region 1537 to 1541 of
16S rRNA Watson-Crick base pairs with this O-mRNA sequence.
Positions 1535 and 1536 in these clones are dominated by
pyrimidines. A third class of pairs (C9, D10) contains the sequence
AUCCC -6 (SEQ ID NO: 11) to AUG in the O-mRNA. The region 1536 to
1540 of the 16S rRNA Watson-Crick base pairs with the O-mRNA.
[0096] The selected rRNA sequences have between 5 and 8 mutations
with respect to the wild-type rRNA sequence, making it likely that
they will discriminate against the translation of endogenous
transcripts. Moreover, since cells have been grown for many
generations in the presence of the mutant ribosomes, it is likely
that the selected mutant ribosomes do not mis-regulate proteome
synthesis. Indeed, negative selection against proteome
mis-regulation may be responsible for the strong convergence of
residues 1535 and 1536 which lie outside the Watson-Crick paired
region of the selected ribosome mRNA interactions, but form key G-C
base pairs in the classic SD ASD helix. To demonstrate that the
mutant ribosomes do not detrimentally mis-regulate the translation
of transcripts that affect cell viability ribosome synthesis was
induced and cell growth was monitored over ten hours (FIG. 4c). In
contrast to designed "specialized ribosomes" that lyse cells after
3 hours (Hui, A. & de Boer, H. A., Supra), Lee, K. et al.,
Supra, Wood, T. K. & Peretti, S. W., Biolechnol. Bioeng 38,
891-906 (1991)), the selected ribosomes, do not lyse cells, and
cells transformed with these ribosomes double at the same rate as
cells containing wild-type ribosomes. Moreover, several of the
selected rRNA sequences have been transferred to the constitutive
and strong P1P2 promoter (from which wild-type rRNA is synthesized)
without significantly affecting cell growth.
[0097] To globally assess the extent of mutant ribosome
orthogonality with respect to all cellular transcripts, cellular
ribosomes were inactivated using spectinomycin and translation was
measured from mutant ribosomes, which are spectinomycin-resistant
by virtue of a C1192U mutation in 16S IRNA (Sigmund, C. D.,
Ettayebi, M. & Morgan, E. A., Nucleic Acids Res 12, 4653-4663
(1984)), (FIG. 4d). The methods used are described briefly as
follows: GH371/rRNAlib/mRNAlib clones were grown to saturation in
LB GAT. The cells were pelleted by centrifugation at 3000 g and
resuspended at OD.sub.600=0.1 in M9 minimal media supplemented with
2% glycerol, all nineteen natural amino acids except methionine, 25
.mu.g ml.sup.-1 ampicillin, 7.5 .mu.g ml.sup.-1 tetracycline. Cells
were incubated (37.degree. C., 300 rpm, 1h), and then pelleted
before resuspension in an equal volume of identical medium, with
the addition of 1 mM IPTG. After incubation (37.degree. C., 300
rpm, 1 h), spectinomycin (500 .mu.g ml.sup.-1) was added to the
media to inhibit endogenous protein synthesis. After a further 10
minutes (Rasmussen, et al., Supra). .sup.35S methionine (>1000
Ci mmol.sup.-1, Amersham) was added to a final concentration of 30
nM. Cells were grown for a further 3 hours, and harvested by
centrifugation. Cells (diluted to OD.sub.600=0.1) were lysed by
boiling in SDS loading buffer. The resulting lysate was chilled on
ice and then separated by 4-12% SDS-PAGE (200V, 35 min). The gel
was dried and imaged on a Storm 840 Phosphoimager (Amersham). To
measure the effects of orthogonal pairs on the growth of cells,
GH371 were grown in LB AT, pelleted at 3000 g, diluted to OD
600=0.1 in LB ATI and incubated (37.degree. C., 300 rpm, 10 h)
until saturation. OD.sub.600 measurements were taken every 100
minutes.
[0098] In the absence of their cognate ribosome-binding site,
mutant ribosomes do not synthesize endogenous protein. However, in
the presence of the cat-upp fusion downstream of a cognate ribosome
binding site greater than 90% of spectinomycin-resistant
translation is involved in CAT-UPRT synthesis. Control experiments
with cat-upp on a wild type SD sequence show that the protein is
expressed at levels below many endogenous proteins (not shown),
demonstrating that this result does not come from overexpression of
the cat-upp fusion. The pairs described here are therefore
orthogonal ribosome mRNA pairs (O-ribosome O-mRNA pairs).
Example 4
Boolean Logic With Orthogonal Ribosomes
[0099] To demonstrate the potential of orthogonal ribosome mRNA
pairs for the programmable synthesis of Boolean logic, simple logic
gates were designed for which the output is controlled by an
orthogonal ribosome. The components of the circuit are an
O-ribosome, a gene encoding the .alpha.-fragment of
.beta.-galactosidase on the corresponding orthogonal SD sequence
(Ullmann, A., Jacob, F. & Monod, J., J Mol Biol 24, 339-343
(1967)), and a gene encoding the .omega. fragment of
.beta.-galactosidase on a wild-type SD sequence (Ullmann, et al.,
Supra). Constructs and methods used are detailed briefly as
follows. A plasmid expressing .beta.-galactosidase .alpha.-fragment
was constructed by replacing the cat-upp fusion gene in p21 with a
PCR fragment of the E. coli lacZ gene downstream of an mRNA-C or
mRNA-A SD sequence. rRNA-9 or rRNA-2 was transformed with or
without a p21-derivative, containing the a complementing fragment
of lacZ downstream of the cognate RBS, into DH10B or BW26444 cells
(a generous gift of B. L. Wanner, Purdue University, West
Lafayette). DH10B cells produce the .omega. fragment of
.beta.-galactosidase due to a chromosomal deletion within lacZ
corresponding to amino acids 11-41. lacZ is completely deleted from
BW26444 (.DELTA.(araD-araB)567, .DELTA.(lacA-lacZ)519(::FRT),
lacIp-4000(lacI.sup.Q), .lamda.., rpoS396(Am), rph-1,
.DELTA.(rhaD-rhaB)568, hsdR514). Cells were recovered in SOB with
2% glucose and transferred to LB GAT and grown overnight at 200
rpm. Cells (100 .mu.l) were transferred to each well of a 96 well
culture block and pelleted by centrifugation at 3000 g. Cells were
resuspended in 1 ml LB AT, incubated (37.degree. C., 300 rpm, 1 h)
and then pelleted at 3000 g. Cell pellets were resuspended in an
equal volume of LB ATI and incubated (37.degree. C., 300 rpm, 3.5
h), before being arrayed using a 96 well pin tool on LB ATI agar
containing 30 .mu.g ml.sup.-1
3,4-cyclohexenoesculetin-.beta.-D-galactopyranoside (S-gal) and 50
.mu.g ml.sup.-1 ferric ammonium citrate.
[0100] As predicted based on the measured specificities of each of
these molecules, these components form an AND function in which the
assembly of functional .beta.-galactosidase is dependent on the
presence of the each of the three components (FIG. 5a).
[0101] It is demonstrated herein that the selected orthogonal pairs
have predictable and defined specificities with respect to the
wild-type ribosome and with respect to each other. These known
relationships allow the programmed synthesis of Boolean operators
for the post-transcriptional regulation of gene expression, and
will facilitate the synthesis of more complex Boolean networks. For
example, it is possible to synthesize two of the three fundamental
operators, and or, using only the ribosomes and binding sites
described here. Combinations of the ribosomes reported here and
other cellular components, with defined molecular specificities,
should lead to sophisticated, yet programmable,
post-transcriptional gene regulatory networks, for the logical
synthesis of complex cellular function.
[0102] His specifically noted that Boolean logic can come from the
simultaneous use of multiple (e.g., 2 or more, 3 or more, 5 or
more, 10 or more, 20 or more, etc.) orthogonal ribosome
orthogonal-mRNA pairs in a single cell. To this end, mRNA-C and
mRNA-A were placed upstream of two otherwise identical .alpha.
fragment genes in a strain of E. coli expressing the .omega.
fragment in excess. Cells were transformed with plasmid DNA
encoding both rRNA-9 and rRNA-2, or one or the other mutant rRNA
and a wild type rRNA. Cells were processed as described above. As
predicted, each mutant rRNA led to .beta. galactosidase activity,
but cells transformed with both mutant rRNAs led to enhanced .beta.
galactosidase activity. At low .beta. galactosidase activity
thresholds, this demonstrates an OR function and at high thresholds
an AND function. These experiments further demonstrate for the
first time that multiple mutant rRNAs can be used to produce
multiple mutant ribosome populations in the cell simultaneously,
demonstrating the possibility to synthesize of logical operators
composed entirely of ribosomes.
Example 5
Boolean Logic with Orthogonal Ribosomes
[0103] The network of molecular specificites of each O-ribosome,
with respect to both cognate and non-cognate orthogonal ribosome
binding sites on mRNA, has been defined by considering each
pairwise O-ribosome.O-mRNA interaction in isolation. Pairs of
O-ribosome.O-mRNA pairs have the molecular specificities that
define mutual orthogonality. For example, O-ribosome-A translates
its cognate O-mRNA-A, but not the non-cognate O-mRNA-C, and
O-ribosome-C translates its cognate O-mRNA-C, but not the
non-cognate O-mRNA-A. Similarly, O-ribosome-B.O-mRNA-B and
O-ribosome-C.O-mRNA-C are mutually orthogonal (FIG. 7). (See also
Rackham & Chin, 2005, J. Am. Chem Soc. 127(50):17584-5, which
is incorporated herein by reference in its entirety). In this
Example it is shown that subnetworks of this network graph can be
physically realized in a single cell and allow combinatorial
cellular programming of entirely post-transcriptional Boolean logic
functions.
[0104] The requirements for the realization of subnetworks are that
multiple distinct ribosome.mRNA pairs can be produced in a single
cell and that these pairs function independently of other
ribosome.mRNA pairs in this context. The simultaneous expression of
multiple distinct mutant ribosomes in cells has not previously been
demonstrated. It requires the expression and processing of two
ribosomal RNAs from two compatible plasmids. It also requires that
ribosomal proteins are produced from the genome in sufficient
quantities to produce functional ribosomes containing wild-type
ribosomal RNA as well as two functional orthogonal ribosomes, which
each contain a distinct O-rRNA.
[0105] As a first step toward the simultaneous production of three
ribosomes in the cell (the wild-type ribosome and two O-ribosomes),
O-rRNAs were produced from plasmids of distinct compatibility
groups and the resulting ribosomes assayed for function.
Construction of compatible rRNA input plasmids
[0106] The RSF rRNA expression plasmid was derived from the
previously described Col El expression plasmid (pTrc16S23S; Rackham
& Chin, 2005, Nature Chem. Biol. 1: 159-166). The RSF1030
replicon, containing a kanamycin resistance gene, was amplified by
PCR from pRSFDuet-1 (Novagen) using the oligonucleotides
5'-AACTAGGGTACCGAATTCGGGCCTCTAAACGGGTCTTGAGG-3' (SEQ ID NO: 120)
and 5'-ATTGCAGCATGCCATATGGTAACGGAATAGCTGTTCGTTGAC-3' (SEQ ID NO:
121). The resulting PCR product was digested with Kpn I and Sph I
and used to replace the Kpn I, Sph I replicon-containing portion of
pTrc 16S23S ribosome plasmids. CAT activity assays for orthogonal
ribosome activity were performed as described in Rackham &
Chin, 2005, supra).
Construction of logic gate plasmids
[0107] p21, a p15A plasmid containing a cat-upp fusion was used to
create the logic gate plasmids. An .omega. allele of lacZ (M15,
deletion of amino acids 11-41) was created by performing enzymatic
inverse PCR on pTrcHis2/lacZ (Invitrogen), using the following
oligonucleotides
5'-GCGAGGAAAGGTCTCATCGTCGCCCTTCCCAACAGTTGCGCAGCCTG-3' (SEQ ID NO:
122) and 5'-AGGGAGTAGGTCTCAACGACGTTGTAAAACGACGGGATCTATC-3' (SEQ ID
NO: 123). .omega. fragments containing mutant ribosome binding
sites were generated by PCR using this .omega. derivative of
pTrcHis2/lacZ as a template and oligonucleotides flanking the gene.
.alpha. fragment genes with altered ribosome binding sites were
created by PCR with pTrcHis2/lacZ as a template. To generate AND
logic gate plasmids the p21 backbone, and a fragments containing
two distinct ribosome binding sites were digested and combined in a
three-way ligation. To generate OR logic gates one .alpha. fragment
gene was replaced by an .omega. fragment gene in the ligation. The
plasmid maps of each resulting logic gate plasmid are included
below (See "Supplementary Plasmid Maps").
Measuring logic function output
[0108] The AND function was created in BW26444 cells, which are
deleted in lacZ. Their genotype is (.DELTA.(araD-araB)567,
.DELTA.(lacA-lacZ)519(::FRT), laclp-4000(lacl.sup.Q), .lamda..,
rpoS396(Am), rph-I, .DELTA.(rhaD-rhaB)568, hsdR514). Heat shock
competent BW26444 cells containing the logic gate plasmid were
prepared by standard CaCl.sub.2 treatment, and combinations of rRNA
inputs accessed by double transformation. Transformed cells were
recovered in SOB with 2% glucose and transferred to LB agar
containing 2% glucose, 50 .mu.g ml.sup.-1 ampicillin, 25 .mu.g
ml.sup.-1 kanamycin, 12.5 .mu.gml.sup.-1 tetracycline and incubated
(16 h, 37.degree. C.). Individual colonies were transferred to each
well of a 96 well culture block containing 100 .mu.l of media (LB
containing 2% glucose, 50 .mu.g ml.sup.-1 ampicillin, 25 .mu.g
ml.sup.-1 kanamycin, 12.5 .mu.g ml.sup.-1 tetracycline) and grown
overnight. Cells were pelleted by centrifugation (3000 g, 5 min)
and resuspended in 1 ml of LB containing 50 .mu.g ml.sup.-1
ampicillin, 25 .mu.g ml.sup.-1 kanamycin, 12.5 .mu.g ml.sup.-1
tetracycline. After a futher 1 h incubation (37 .degree. C., 250
rpm) cells were supplemented with
isopropyl-.beta.-D-thiogalactopyranoside (to 1 mM), and incubated
(37.degree. C., 250 rpm, 4h) and the OD.sub.600 measured. Cells
were pelleted at 3000 g, resuspended in 100 .mu.L BugBuster HT
(Novagen) and permealised by shaking for 25 minutes. An equal
volume of 2 x buffer Z (120 mM Na.sub.2HPO.sub.4, 80 mM
NaH.sub.2PO.sub.4, 20 mM KCl, 2 mM MgSO.sub.4, 100 mM
.beta.-mercaptoethanol) containing fluorescein
di-.beta.-D-galactopyranoside (Molecular Probes, final
concentration 0.5 mM) was added and incubated (22.degree. C.) until
a strong fluorescent signal was detected (approximately 5 min).
Cells and debris were pelleted and the clarified supernatant
transferred to a 96 well plate. Fluorescence was detected using a
Spectra Max Gemini XS (Molecular Devices), with excitation at 370
nm and emission detection at 450 nm.
Fluorescence was normalized for cell density and time of incubation
with .beta.-galactosidase substrate, using the equation:
Fluorescence=1000 x (raw fluorescence.sub.450 nm)/(t.V.OD.sub.600)
Where (t) is time of incubation in seconds and (V) is the volume of
culture used.
[0109] The OR function was created in DH10OB E. coli , which
produce the .omega. fragment of .beta.-galactosidase due to a
chromosomal deletion corresponding to amino acids 11-41 within the
lacZ gene. This strain has the following genotype: (F-, mcrA,
.DELTA.(mrr-hsdRMS-mcrBC), .DELTA.(lacZ)M15, .DELTA.lacX74, recA1,
araD139, .DELTA.(ara-leu)7697, galU, galK, rpsL(StrR), endA1,
nupG). The other experimental procedures were as described above
for the AND function.
[0110] One vector for rRNA production has a Co1E1 origin of
replication and an ampicillin resistance gene and is present at
about 50 copies per cell. A second vector for rRNA production has
an RSF origin of replication and a kanamycin resistance gene, and
is present at about 100 copies per cell. The inventors have
previously observed that the production of functional ribosomes
incorporating plasmid-encoded rRNA can be strongly modulated by the
sequences flanking the rRNA transcriptional cassette. To ascertain
the effect of plasmid flanking sequences and plasmid copy number on
the activity of the O-ribosomes incorporating plasmid-encoded rRNA,
the translation of the chloramphenicol acetyl transferase gene
(cat) from O-mRNA-Ccat (a version of cat with the 5' orthogonal
ribosome binding site C) was measured. Cells containing RSF or
Co1E1 plasmids encoding rRNA-C confer resistance to
chloramphenicol, with IC.sub.50s of 250 .mu.g mL.sup.-1 and 150
.mu.g mL.sup.-1 respectively, while O-mRNA-Ccat has an IC.sub.50 of
10 .mu.g mL.sup.-1 in the absence of cognate ribosome. Similar
results were obtained with other O-ribosome.O-mRNA pairs. These
results demonstrate that highly active orthogonal ribosomes can be
produced from two compatible plasmids, and that the RSF plasmid
leads to a slightly greater ribosome activity than the Co1E1
plasmid, as predicted based on copy number alone.
[0111] To demonstrate that multiple O-ribosomes can be produced in
a single cell, and to begin to address the potential of O-ribosomes
for the expression of Boolean logic, an AND gate containing O-mRNA
sequences was designed. The gate is composed of two O-mRNA
sequences: O-mRNA-A.omega. directs the synthesis of the .omega.
fragment of (.beta.-galactosidase, while O-mRNA-C.alpha. directs
the synthesis of the .alpha. fragment of .beta.-galactosidase. Upon
synthesis and assembly of both fragments into .beta.-galactosidase
((.alpha.+.omega.).sub.4), cells hydrolyse fluorescein
di-.beta.-D-galactopyranoside (FDG) to fluorescein (F), which can
be detected fluorimetrically (FIG. 8a, b).
[0112] Cells containing a plasmid encoding both O-mRNA-C.alpha. and
O-mRNA-A.omega. were programmed with either wild-type rRNA, rRNA-A,
rRNA-C or rRNA-C and rRNA-A together, and the conversion of FDG to
fluorescein measured. Cells programmed with wild-type rRNA produce
low fluorescence, which is comparable to background. This confirms
that the orthogonal ribosome binding sites A and C--developed on
the cat gene--are portable, and can confer orthogonality to a
variety of genes. Cells programmed with rRNA-A also produce low
fluorescence, as do cells programmed with rRNA-C. However cells
programmed with both rRNA-A and rRNA-C give a fluorescent signal
20-fold greater than other rRNA combinations. These data
demonstrate that multiple mutually orthogonal ribosomes can be
functionally expressed in a single cell. Moreover they show that
rRNA-A and rRNA-C can be used as inputs in a post-transcriptional
AND function. Similar AND functions were also obtained with cells
containing other mutually orthogonal ribosomes and their cognate
O-mRNA.alpha.s and O-mRNA.omega.s.
[0113] Next, a Boolean OR gate was created. The OR gate is composed
of two O-mRNAs (O-mRNA-A.alpha. and O-mRNA-C.alpha.) each of which
directs the synthesis of the a fragment of .beta.-galactosidase
(FIG. 8 c, d). In this system the .omega. fragment is
constitutively produced from a wild-type ribosome binding site.
Cells programmed with wild-type ribosomes produce a fluorescence
comparable to that observed in the absence of plasmid-encoded
.alpha. fragment. Cells programmed with rRNA-A produce a
fluorescence signal 10-fold above background, while cells
programmed with rRNA-C produce a level of fluorescence 15-fold
above background. Cells programmed with both rRNA-C and rRNA-A give
a fluorescent signal more than 50-fold above background. The
increase in fluorescent signal indicates that in this system the
.omega.-fragment is present in excess of the .alpha.-fragment
though each is produced from single gene present at identical copy
number and using the same promoter and terminator. When wild-type
ribosome binding sites are used to replace the orthogonal ribosome
binding sites on the mRNA a similar result is observed. This
suggests that the mismatch in cellular concentration of
.omega.-fragment and .alpha.-fragment result from a deficiency in
either the transcription or lifetime of the .alpha.-fragment mRNA,
or degradation of the .alpha.-fragment peptide. Overall, these
results demonstrate that rRNA-A and rRNA-C can be used as inputs in
a Boolean OR function. The OR function can also be created using
other mutually orthogonal rRNAs and cognate O-mRNAs.
[0114] In conclusion, it is demonstrated that O-ribosomes and
O-mRNAs can be used to create entirely post-transcriptional
combinatorial logic in living cells. The Boolean gates described
require multiple distinct orthogonal ribosomes as inputs and could
not be assembled using the wild-type ribosome, since its removal
from the cell is lethal, precluding a value of zero for its input.
Demonstrated herein is how unnatural, orthogonal, modular
components and a knowledge of the non-covalent interactions between
components can be used to synthesize unnatural network
architectures and logical functions in living matter.
Example 6
Predicting a Network of O-Ribosome O-mRNA Pairs
[0115] Amongst the three orthogonal ribosome mRNA pairs described
there are nine potential ribosome mRNA interactions, most of which
are of unknown, and potentially varying, strength. Calculations on
genomic sequences, using Turner's rules (Freier, S. M. et al., Proc
Nail Acad Sci USA 83, 9373-9377 (1986), Freier, S. M., Kierzek, R.,
Caruthers, M. H., Neilson, T. & Turner, D. H., Biochemistry 25,
3209-3213 (1986)), have shown that there is a signature drop in the
free energy of rRNA mRNA base pairing of between 4 and 5 kcal
mol.sup.-1 for translational start sites relative to the rest of
the genome (Schurr, T., Nadir, E. & Margalit, H., Nucleic Acids
Res 21, 4019-4023 (1993), Osada, Y., Saito, R. & Tomita, M.,
Bioinformatics 15, 578-581 (1999)). Unlike genomic transcripts, the
O-mRNAs described herein have a region of variable sequence
surrounded by common flanking sequence, and it was reasoned that
this may make their translation by O-ribosomes even more
predictable. The .DELTA.G of association was calculated for the
most stable base-pairing alignment of the 3' end of mutant rRNAs
and cognate and non-cognate O-mRNAs using Turner's rules. This
produced calculated free energies for O-ribosome O-mRNA pairs of
between 0 and 10 kcal mol.sup.-1 (Table 2).
TABLE-US-00002 TABLE 2 The predicted and measured specificities of
orthogonal ribosomes on cognate- and non-cognate-orthogonal
ribosome binding sites. O-mRNA B A C O- Ribosome .DELTA.G.sup.a
.DELTA..DELTA.G.sup.b IC.sub.50.sup.c .DELTA.G.sup.a
.DELTA..DELTA.G.sup.b IC.sub.50.sup.c .DELTA.G.sup.a
.DELTA..DELTA.G.sup.b 9 -1.5 -7.5 10 -2.9 -6 10 -9.0 0 2 -6.3 -2.7
50 -8.9 0 200 -2.9 -6.1 8 -9.0 0 150 -2.1 -6.8 10 -0.7 -8.3
.sup.a.DELTA.G (kcal mol.sup.-1) calculated for the base pairing
interaction using Turner's rules. .sup.b.DELTA..DELTA.G =
.DELTA.G.sub.[cognate site] - .DELTA.G.sub.[non-cognate site].
.sup.cIC.sub.50 (.mu.g ml.sup.-1) of chloramphenicol resistance.
indicates data missing or illegible when filed
[0116] Cells were then transformed with all combinations of
O-ribosomes and O-mRNAs and measured the chloramphenicol resistance
generated from the O-cat-upp reporters (FIG. 5b). From the free
energy values and IC.sub.50 values a predicted-and an
experimental-network graph was generated, in which the lines
representing the interactions between O-ribosomes and O-mRNAs have
a grey scale value between 0 and 100 that corresponds linearly with
the predicted free energy of base-pairing or the IC.sub.50 value of
Chloramphenicol resistance respectively (FIG. 5c). The correlation
between the predicted network of interaction strengths and the
observed network is striking. To calculate a simple measure of the
upper limit of the likelihood of predicting the correct network
graph by chance a simple case in which the nine ribosome mRNA
interactions are digitized was considered. There are 512 (2.sup.9)
distinct ways in which three ribosomes can interact with three
mRNAs. Each of these solutions describes a specific network of
interactions, and can be represented by a unique network graph. The
upper limit of likelihood that free energy calculations could
correctly predict all nine interactions in the graph is therefore 1
in 512.
As suggested by the free energy calculations, it was found that
ribosomes containing rRNA-9 function with mRNA-C, but not mRNA-A or
mRNA-B, ribosomes containing rRNA-8 function with mRNA-B, but not
with mRNA-A or mRNA-C, and ribosomes containing rRNA-2 function
with mRNA-A and also with mRNA-B. It is interesting to note that
the free energy calculations predict that the rRNA-2 mRNA-B
interaction will be weaker than the rRNA-2 mRNA-A pair interaction
and a corresponding difference is seen in the experimental
IC.sub.50 values. The C9 ribosome mRNA pair is mutually orthogonal
with the A2. ribosome mRNA pair, and mutually orthogonal with the
B8 ribosome mRNA pair. Ribosomes bearing rRNA-8 are orthogonal to
the mRNA-A, but ribosomes bearing rRNA-2 function with mRNA-B.
Moreover, comparison of the aligned sequences of rRNA-2 mRNA-B and
rRNA-8 mRNA-A pairs provides a molecular basis for their different
behavior. The rRNA-2 mRNA-B pair contains two G-U base-pairs, that
stabilize the interaction. However the corresponding A-C mismatches
in the rRNA-8 mRNA-A pair are destabilizing. The stability of the
G-U pair breaks the symmetry of interactions predicted based on
Watson-Crick base pair interactions and provides a mechanism by
which functional connections between ribosomes and mRNAs in a
synthetic network can become asymmetric.
OTHER EMBODIMENTS
[0117] All patents, patent applications, and published references
cited herein are hereby incorporated by reference in their
entirety. While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
TABLE-US-00003 APPENDIX 1 Oligonucleotides Used in the Described
Examples Name Sequence (5'-3') Purpose 16SClaXhoF
GAATTTATCGATACTCGAGGCCGCTGAGAAA Creating Xho I site 5' of 16S gene
AAGCGAAGC (SEQ ID NO: 12) 16SXbaR TGGGCCTCTAGACGAAGGGGACACGAAAATT
Amplification of 16S in combination with G (SEQ ID NO: 13)
16SClaXhoF 72MCSnoBsaF GATGATATCAGATCTGCCGCTCTCCCTATAGT Mutation of
Bsa I site in MCS of pSP72 in GAGTC (SEQ ID NO: 14) combination
with 72MCSnoBsaR 72MCSnoBsaR GACTCACTATAGGGAGAGCGGCAGATCTGAT
Mutation of Bsa I site in MCS of pSP72 in ATCATC (SEQ ID NO: 15)
combination with 72MCSnoBsaF 73MCSnoBsaF
CTTCAGCTGCTCGAGGCCGCTCTCCCTATAGT Mutation of Bsa I site in MCS of
pSP73 in GAGTCG (SEQ ID NO: 16) combination with 73MCSnoBsaR
73MCSnoBsaR CGACTCACTATAGGGAGAGCGGCCTCGAGCA Mutation of Bsa I site
in MCS of pSP73 in GCTGAAG (SEQ ID NO: 17) combination with
73MCSnoBsaF SPampnoBsaF GGAGCCGGTGAGCGTGGCTCTCGCGGTATCA Mutation of
Bsa I site in AmpR gene of TTG (SEQ ID NO: 18) pSP72/73 in
combination with SPampnoBsaR SPampnoBsaR
CAATGATACCGCGAGAGCCACGCTCACCGGC Mutation of Bsa I site in AmpR gene
of TCC (SEQ ID NO: 19) pSP72/73 in combination with SPampnoBsaF
minusPstIF CTGAAGCTTGCATGCCCGCAGGTCGACTCTA Mutation of Pst I site
in MCS of pSP72/73 G (SEQ ID NO: 20) in combination with minusPstIR
minusPstIR CTAGAGTCGACCTGCGGGCATGCAAGCTTCA Mutation of Pst I site
in MCS of pSP72/73 G (SEQ ID NO: 21) in combination with minusPstIF
23SnoBsaAUf CTGGGGCGGTCACCTCCTAAAGAGTAACGGA Mutation of Bsa I site
in 23S rRNA gene in GGTGCACGAAGGTTG (SEQ ID NO: 22) combination
with 23SnoBsaAUr 23SnoBsaAUr CAACCTTCGTGCACCTCCGTTACTCTTTAGGA
Mutation of Bsa I site in 23S rRNA gene in GGTGACCGCCCCAG (SEQ ID
NO: 23) combination with 23SnoBsaAUf 5SnoBsaC2Uf
GATGGTAGTGTGGGGTTTCCCCATGCGAGAG Mutation of Bsa I site in 5S rRNA
gene in TAG (SEQ ID NO: 24) combination with 5SnoBsaC2Ur
5SnoBsaC2Ur CTACTCTCGCATGGGGAAACCCCACACTACC Mutation of Bsa I site
in 5S rRNA gene in ATC (SEQ ID NO: 25) combination with 5SnoBsaC2Uf
pBR322SeqF TGTCTGCTCCCGGCATCCGCTTACAG For amplification of minimal
pTrc promoter (SEQ ID NO: 26) in combination with TrcpromR TrcpromR
ATTCCGCTCGAGTGCCCACACAGATTGTCTG For amplification of minimal pTrc
promoter ATAAATTG (SEQ ID NO: 27) in combination with pBR322SeqF
KanF CAGTAACTCGAGCGGCCGCATGAGCCATATT For amplification of KanR gene
in CAACGGGAAACGTCTTGTTCGAGGCCGCGAT combination with KanR TAAATTC
(SEQ ID NO: 28) KanR GCTTTGGAATTCCCGGGAATCGATGGTACCA For
amplification of KanR gene in GATCTGGATCCTCCGGCGTTCAGCCTGTG
combination with KanF (SEQ ID NO: 29) AmpNgoMIVF
GAGTTGCTCTTGGCCGGCGTCAATACGGGAT For introduction of NgoM IV site in
AmpR AATAC (SEQ ID NO: 30) gene of pSP72/73 in combination with
AmpNgoMIVR AmpNgoMIVR GTATTATCCCGTATTGACGCCGGCCAAGAGC For
introduction of NgoM IV site in AmpR AACTC (SEQ ID NO: 31) gene of
pSP72/73 in combination with AmpNgoMIVF SD1libF
GGAAAGGTCTCAGGTTGGATCANNNNNNTAC For randomization of anti-SD in 16S
rRNA CTTAAAGAAGCGTACTTTGTAG gene in combination with SD1libR (SEQ
ID NO: 32) SD1libR GAGTAGGTCTCAAACCGCAGGTTCCCCTACG For
randomization of anti-SD in 16S rRNA (SEQ ID NO: 33) gene in
combination with SD1libF SD2libF GGAAAGGTCTCAGAATACCGNNGGCGAAGG For
randomization of 722, 723 in 16S rRNA CGGCCCCCTGGACGAA (SEQ ID NO:
34) gene in combination with SD2libR SD2libR
GAGTAGGTCTCAATTCCTCCAGATCTCTACGC For randomization of 722, 723 in
16S rRNA ATTTCAC (SEQ ID NO: 35) gene in combination with SD2libF
RBSlib7F GGGAAAGGTCTCCCGCTTTCANNNNNNNCCG For randomization of RBS
in p21 in CAAATGGAGAAAAAAATCACTGGATATACC combination with RBSlib7R
(SEQ ID NO: 36) RBSrev GGAGTAGGTCTCAAGCGGCCGCTTCCACACA For
randomization of RBS in p21 in TTAAACTAGTTC (SEQ ID NO: 37)
combination with RBSlib7F wtRBSnoATGf
GCGCAGGAAAGGTCTCAGCCGCTTTCAGGAG Mutation of AUG start codon of
cat-upp GCTCGAGAACCCGAGAAAAAAATCACTGGAT gene in p21 to CCC in
combination with ATACCACCG (SEQ ID NO: 38) wtRBSrev wtRBSrev
GCGCAGAGTAGGTCTCACGGCCGCTTCCACA Mutation of AUG start codon of
cat-upp CATTAAACTAGTTCG (SEQ ID NO: 39) gene in p21 to CCC in
combination with wtRBSnoATGf wtRBSfwd
GCGCAGGAAAGGTCTCAGCCGCTTTCAGGAG Deletion of promotor of cat-upp
gene in p21 GCTCGAGAAATGGAGAAAAAAATCACTGGA in combination with
noPROMrev TATACCACC (SEQ ID NO: 40) noPROMrev
GCGCAGAGTAGGTCTCACGGCAGGGCCCTAC Deletion of promotor of cat-upp
gene in p21 GTGCCGATCAACGTCTC (SEQ ID NO: 41) in combination with
wtRBSfwd RSFfwd AACTAGGGTACCGAATTCGGGCCTCTAAACG Amplification of
RSF ori and KanR gene GGTCTTGAGG (SEQ ID NO: 42) fragment from
pRSFDuet-1 in combination with RSFrev RSFrev
ATTGCAGCATGCCATATGGTAACGGAATAGC Amplification of RSF ori and KanR
gene TGTTCGTEGAC (SEQ ID NO: 43) fragment from pRSFDuet-1 in
combination with RSFfwd ACYCNotfwd ATGAAAGCGGCCGCTTCCACACATTAAACTA
Amplification of p21 backbone fragment in GTTCG (SEQ ID NO: 44)
combination with ACYCBglrev ACYCBglrev
GGTACGAGATCTAGAATTCGAAGCTTGGGCC Amplification of p21 backbone
fragment in CGAACA (SEQ ID NO: 45) combination with ACYCNotfwd
G9alphaF GTGGAAGCGGCCGCTTTCATATCCCTCCGCA Amplification of alpha
complementing lacZ AATGCCCGTCGTTTTACAACGTCGTGAC gene fragment with
G9 RBS in combination (SEQ ID NO: 46) with alphaR alphaR
TTGACAAGATCTGAATTCCCATGGATAAAAC Amplification of alpha
complementing lacZ GAAAGGCCCAGTCTTTCGACTGAGCCTTTCG gene fragment
with G9 RBS in combination TTTTATTTGTTAATCGTAACCGTGCATCTGCC with
G9alphaF AG (SEQ ID NO: 47)
Sequence CWU 1
1
12915RNAEscherichia coli 1ggagg 525RNAEscherichia coli 2ccucc
5361DNAartificial sequenceMutagenic PCR primer 3gggaaaggtc
tcccgctttc annnnnnncc gcaaatggag aaaaaaatca ctggatatac 60c
61443DNAartificial sequenceReverse PCR primer for mutagenesis
4ggagtaggtc tcaagcggcc gcttccacac attaaactag ttc 43553DNAartificial
sequenceMutagenic PCR primer 5ggaaaggtct caggttggat cannnnnnta
ccttaaagaa gcgtactttg tag 53631DNAartificial sequenceReverse PCR
primer for mutagenesis 6gagtaggtct caaaccgcag gttcccctac g
31746DNAartificial sequenceMutagenic PCR primer 7ggaaaggtct
cagaataccg nnggcgaagg cggccccctg gacgaa 46839DNAartificial
sequenceReverse PCR primer for mutagenesis 8gagtaggtct caattcctcc
agatctctac gcatttcac 3995RNAartificial sequenceSelected cognate
ribosome mRNA sequence 9accac 5105RNAartificial sequenceSelected
cognate ribosome mRNA sequence 10acugc 5115RNAartificial
sequenceSelected cognate ribosome mRNA sequence 11auccc
51240DNAartificial sequencecloning oligonucleotide 12gaatttatcg
atactcgagg ccgctgagaa aaagcgaagc 401332DNAartificial
sequenceCloning oligonucleotide 13tgggcctcta gacgaagggg acacgaaaat
tg 321437DNAartificial sequenceCloning oligonucleotide 14gatgatatca
gatctgccgc tctccctata gtgagtc 371537DNAartificial sequenceCloning
oligonucleotide 15gactcactat agggagagcg gcagatctga tatcatc
371638DNAartificial sequenceCloning oligonucleotide 16cttcagctgc
tcgaggccgc tctccctata gtgagtcg 381738DNAartificial sequenceCloning
oligonucleotide 17cgactcacta tagggagagc ggcctcgagc agctgaag
381834DNAartificial sequenceCloning oligonucleotide 18ggagccggtg
agcgtggctc tcgcggtatc attg 341934DNAartificial sequenceCloning
oligonucleotide 19caatgatacc gcgagagcca cgctcaccgg ctcc
342032DNAartificial sequenceCloning oligonucleotide 20ctgaagcttg
catgcccgca ggtcgactct ag 322132DNAartificial sequenceCloning
oligonucleotide 21ctagagtcga cctgcgggca tgcaagcttc ag
322246DNAartificial sequenceCloning oligonucleotide 22ctggggcggt
cacctcctaa agagtaacgg aggtgcacga aggttg 462346DNAartificial
sequenceCloning oligonucleotide 23caaccttcgt gcacctccgt tactctttag
gaggtgaccg ccccag 462434DNAartificial sequenceCloning
oligonucleotide 24gatggtagtg tggggtttcc ccatgcgaga gtag
342534DNAartificial sequenceCloning oligonucleotide 25ctactctcgc
atggggaaac cccacactac catc 342626DNAartificial sequenceCloning
oligonucleotide 26tgtctgctcc cggcatccgc ttacag 262738DNAartificial
sequenceCloning oligonucleotide 27attccgctcg agtgcccaca cagattgtct
gataaatt 382869DNAartificial sequenceCloning oligonucleotide
28cagtaactcg agcggccgca tgagccatat tcaacgggaa acgtcttgtt cgaggccgcg
60attaaattc 692960DNAartificial sequenceCloning oligonucleotide
29gctttggaat tcccgggaat cgatggtacc agatctggat cctccggcgt tcagcctgtg
603036DNAartificial sequenceCloning oligonucleotide 30gagttgctct
tggccggcgt caatacggga taatac 363136DNAartificial sequenceCloning
oligonucleotide 31gtattatccc gtattgacgc cggccaagag caactc
363253DNAartificial sequenceCloning oligonucleotide 32ggaaaggtct
caggttggat cannnnnnta ccttaaagaa gcgtactttg tag 533331DNAartificial
sequenceCloning oligonucleotide 33gagtaggtct caaaccgcag gttcccctac
g 313446DNAartificial sequenceMutagenic cloning oligonucleotide
34ggaaaggtct cagaataccg nnggcgaagg cggccccctg gacgaa
463539DNAartificial sequenceMutagenic cloning oligonucleotide
35gagtaggtct caattcctcc agatctctac gcatttcac 393661DNAartificial
sequenceMutagenic cloning oligonucleotide 36gggaaaggtc tcccgctttc
annnnnnncc gcaaatggag aaaaaaatca ctggatatac 60c 613743DNAartificial
organismCloning oligonucleotide 37ggagtaggtc tcaagcggcc gcttccacac
attaaactag ttc 433871DNAartificial sequenceCloning oligonucleotide
38gcgcaggaaa ggtctcagcc gctttcagga ggctcgagaa cccgagaaaa aaatcactgg
60atataccacc g 713946DNAartificial organismCloning oligonucleotide
39gcgcagagta ggtctcacgg ccgcttccac acattaaact agttcg
464070DNAArtificial sequenceCloning oligonucleotide 40gcgcaggaaa
ggtctcagcc gctttcagga ggctcgagaa atggagaaaa aaatcactgg 60atataccacc
704148DNAartificial sequenceCloning oligonucleotide 41gcgcagagta
ggtctcacgg cagggcccta cgtgccgatc aacgtctc 484241DNAArtificial
sequenceCloning oligonucleotide 42aactagggta ccgaattcgg gcctctaaac
gggtcttgag g 414342DNAArtificial sequenceCloning oligonucleotide
43attgcagcat gccatatggt aacggaatag ctgttcgttg ac
424436DNAArtificial sequenceCloning oligonucleotide 44atgaaagcgg
ccgcttccac acattaaact agttcg 364537DNAartificial sequenceCloning
oligonucleotide 45ggtacgagat ctagaattcg aagcttgggc ccgaaca
374659DNAArtificial sequenceCloning oligonucleotide 46gtggaagcgg
ccgctttcat atccctccgc aaatgcccgt cgttttacaa cgtcgtgac
594796DNAArtificial sequenceCloning oligonucleotide 47ttgacaagat
ctgaattccc atggataaaa cgaaaggccc agtctttcga ctgagccttt 60cgttttattt
gttaatcgta accgtgcatc tgccag 96486RNAartificial sequenceselected
orthogonal mRNA sequence 48caccac 6497RNAartificial
sequenceSelected orthogonal mRNA sequence 49caacugc
7507RNAartificial sequenceSelected orthogonal mRNA sequence
50caucccu 7515RNAartificial sequenceSelected orthogonal mRNA
sequence 51ucccu 55212RNAartificial sequenceSelected orthogonal
mRNA sequence 52caccacccgc aa 125313RNAartificial sequenceSelected
orthogonal mRNA sequence 53caacugcccg caa 135413RNAartificial
sequenceSelected orthogonal mRNA sequence 54caucccuccg caa
135511RNAartificial sequenceSelected orthogonal mRNA sequence
55ucccuccgca a 11566RNAartificial sequenceorthogonal 16S rRNA
sequence 56aguggu 6576RNAartificial sequenceorthogonal 16S rRNA
sequence 57cugugg 6586RNAartificial sequenceorthogonal 16S rRNA
sequence 58uugugg 6596RNAartificial sequenceorthogonal 16S rRNA
sequence 59uugugg 6606RNAartificial sequenceorthogonal 16S rRNA
sequence 60augcag 6616RNAartificial sequenceorthogonal 16S rRNA
sequence 61uugcag 6626RNAartificial sequenceorthogonal 16S rRNA
sequence 62ucgcag 6636RNAartificial sequenceorthogonal 16S rRNA
sequence 63ccgcag 6646RNAartificial sequenceorthogonal 16S rRNA
sequence 64ugggau 6656RNAartificial sequenceorthogonal 16S rRNA
sequence 65ugggau 6669RNAartificial sequenceorthogonal 16S rRNA
sequence 66ccgaguggc 96712RNAartificial sequenceorthogonal 16S rRNA
sequence 67aucaaguggu ua 12689RNAartificial sequenceorthogonal 16S
rRNA sequence 68ccgcguggc 96912RNAartificial sequenceorthogonal 16S
rRNA sequence 69aucacugugg ua 12709RNAartificial sequenceorthogonal
16S rRNA sequence 70ccgcauggc 97112RNAartificial sequenceorthogonal
16S rRNA sequence 71aucauugugg ua 12729RNAartificial
sequenceorthogonal 16S rRNA sequence 72ccgguuggc 97312RNAartificial
sequenceorthogonal 16S rRNA sequence 73aucauugugg ua
12749RNAartificial sequenceorthogonal 16S rRNA sequence 74ccgacuggc
97512RNAartificial sequenceorthogonal 16S rRNA sequence
75aucaaugcag ua 12769RNAartificial sequenceorthogonal 16S rRNA
sequence 76ccgacuggc 97712RNAartificial sequenceorthogonal 16S rRNA
sequence 77aucauugcag ua 12789RNAartificial sequenceorthogonal 16S
rRNA sequence 78ccgcguggc 97912RNAartificial sequenceorthogonal 16S
rRNA sequence 79aucaucgcag ua 12809RNAArtificial sequenceorthogonal
16S rRNA sequence 80ccgcauggc 98112RNAartificial sequenceorthogonal
16S rRNA sequence 81aucaccgcag ua 128212RNAartificial
sequenceorthogonal 16S rRNA sequence 82aucaugggau ua
12839RNAartificial sequenceorthogonal 16S rRNA sequence 83ccgguuggc
9846RNAartificial sequenceselected orthogonal mRNA sequence
84caccac 6856RNAartificial sequenceSelected orthogonal 16S rRNA
sequence 85aguggu 6866RNAartificial sequenceSelected orthogonal 16S
rRNA sequence 86cugugg 6876RNAartificial sequenceSelected
orthogonal 16S rRNA sequence 87uugugg 6887RNAartificial
sequenceSelected orthogonal 16S rRNA sequence 88caacugc
7896RNAartificial sequenceSelected orthogonal 16S rRNA sequence
89augcag 6906RNAartificial sequenceSelected orthogonal 16S rRNA
sequence 90uugcag 6916RNAartificial sequenceSelected orthogonal 16S
rRNA sequence 91ucgcag 6926RNAartificial sequenceSelected
orthogonal 16S rRNA sequence 92ccgcag 6937RNAartificial
sequenceSelected orthogonal mRNA sequence 93caucccu
7946RNAartificial sequenceSelected orthogonal 16S rRNA sequence
94ugggau 69512RNAartificial sequenceSelected orthogonal mRNA
sequence 95caccacccgc aa 12968RNAartificial sequenceSelected
orthogonal 16S rRNA sequence 96ccgagggc 89712RNAartificial
sequenceSelected orthogonal 16S rRNA sequence 97aucaaguggu ua
12988RNAartificial sequenceSelected orthogonal 16S rRNA sequence
98ccgcgggc 89912RNAartificial sequenceSelected orthogonal 16S rRNA
sequence 99aucacugugg ua 121008RNAartificial sequenceSelected
orthogonal 16S rRNA sequence 100ccgcaggc 810112RNAartificial
sequenceSelected orthogonal 16S rRNA sequence 101aucauugugg ua
121028RNAartificial sequenceSelected orthogonal 16S rRNA sequence
102ccgguggc 810313RNAartificial sequenceSelected orthogonal mRNA
sequence 103caacugcccg caa 131048RNAartificial sequenceSelected
orthogonal 16S rRNA sequence 104ccgacggc 810512RNAartificial
sequenceSelected orthogoanl 16S rRNA sequence 105aucaaugcag ua
1210612RNAartificial sequenceSelected orthogonal 16S rRNA sequence
106aucauugcag ua 121078RNAartificial sequenceSelected orthogonal
16S rRNA sequence 107ccgcgggc 810812RNAartificial sequenceSelected
orthogonal 16S rRNA sequence 108aucaucgcag ua 121098RNAartificial
sequenceSelected orthogonal 16S rRNA sequence 109ccgcaggc
811012RNAartificial sequenceSelected orthogonal 16S rRNA sequence
110aucaccgcag ua 1211113RNAartificial sequenceSelected orthogonal
mRNA sequence 111caucccuccg caa 1311212RNAartificial
sequenceSelected orthogonal 16S rRNA sequence 112aucaugggau ua
121138RNAartificial sequenceSelected orthogonal 16S rRNA sequence
113ccgguggc 811421RNAEscherichia coli 114uuucauagga ggccgcaaau g
211158RNAEscherichia coli 115ccgguggc 811612RNAEscherichia coli
116aucaccuccu ua 1211721RNAartificial sequencerandomized mRNA
sequence for library generation 117uuucannnnn nnccgcaaau g
211188RNAartificial sequence16S rRNA sequence mutated to generate
library 118ccgnnggc 811912RNAartificial sequence16S rRNA sequence
mutated to form library 119aucannnnnn ua 1212040DNAartificial
sequenceCloning oligonucleotide 120aactagggta ccgaattcgg gcctctaaac
gggtcttgag 4012142DNAartificial sequenceCloning oligonucleotide
121attgcagcat gccatatggt aacggaatag ctgttcgttg ac
4212247DNAartificial sequenceCloning oligonucleotide 122gcgaggaaag
gtctcatcgt cgcccttccc aacagttgcg cagcctg 4712343DNAartificial
sequenceCloning oligonucleotide 123agggagtagg tctcaacgac gttgtaaaac
gacgggatct atc 4312420RNAartificial sequenceOrthologous mRNA-A
124uuucacacca cccgcaaaug 2012512RNAartificial sequenceOrthologous
rRNA-A 125aucacugugg ua 1212621RNAartificial sequenceOrthologous
mRNA-B 126uuucacaacu gcccgcaaau g 2112712RNAartificial
sequenceOrthologous rRNA-B 127aucaccgcag ua 1212821RNAartificial
sequenceOrthologous mRNA-C 128uuucacaucc cuccgcaaau g
2112912RNAartificial sequenceOrthologous rRNA-C 129aucaugggau ua
12
* * * * *
References